UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~June 30, ~~2022~~2023

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-39577

Aziyo Biologics, Inc.

(Exact name of registrant as specified in its charter)


Delaware		47-4790334
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

12510 Prosperity Drive, Suite 370

Silver Spring, MD 20904

(Address of principal executive offices and Zip Code)

(240) 247-1170

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common Stock, par value $0.001 per share	AZYO	The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐		Accelerated filer ☐
Non-accelerated filer ☒		Smaller reporting company ☒
		Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~November 11, 2022,~~August 9, 2023, there were ~~9,460,964~~11,936,441 shares of the registrant’s Class A common stock and 4,313,406 shares of the registrant’s Class B common stock outstanding.

Table of Contents

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (the “Quarterly Report”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Quarterly Report, including, without limitation, statements regarding our results of operations, financial position, ~~projected growth in our net sales, increases in expenses, seasonality,~~and business ~~strategy, policies and approach, including, without limitation:~~strategy; expectations regarding our products and their targeted effects; expectations regarding the voluntary recall of a single lot of a certain viable bone matrix product and the market withdrawal of all of our viable bone matrix (“VBM”) products (“VBM Matter”), and any impact of the recall and suspension of sales of these products on the Company’s business; plans for our sales and marketing ~~growth and~~growth; our anticipated expansion of our product development and ~~clinical and~~ research activities; increases in expenses and seasonality; expectations regarding ~~competition,~~ our competitive advantages, ~~regulations that impact our business,~~ and overall clinical and commercial success; expectations regarding the pending lawsuits and claims related to our recall of a single lot of Fiber Viable Bone Matrix (“FiberCel”), amounts recoverable under insurance, indemnity and contribution agreements and the impact of such lawsuits and claims on our future financial position; ~~results~~expectations regarding the potential emergence of ~~operations or business;~~lawsuits and claims related to the VBM Matter, amounts recoverable under insurance, indemnity and contribution agreements and the impact of such lawsuits and claims on our future financial position; our expectations and plans regarding pursuit of any strategic transactions; and our expectations relating to the FDA regulatory process for the CanGaroo RM Antibacterial ~~Envelope; the potential impact of the pandemic related to COVID-19 and variants thereof on our business; plans for meeting our current or future cash requirements~~Envelope are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

Without limiting the foregoing, the words ~~“aim”,~~“aim,” “believe,” “may,” “will,” “should,” “expect,” “exploring,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “seeks,” or “continue” or the negative of these terms or other similar expressions, are intended to identify forward-looking statements, although not all forward-looking statements contain these words.

These forward-looking statements are not a guarantee of future results, performance, or achievements, and one should avoid placing undue reliance on such statements.

These forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to us. Such beliefs and assumptions may or may not prove to be correct. Additionally, such forward-looking statements are subject to a number of known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in the forward-looking statements, including, but not limited to the following:

our ability to continue as a going concern;

●

our ability to achieve or sustain profitability;

●

our ability to obtain regulatory approval or other marketing authorizations by the U.S. Food and Drug Administration (“FDA”) and comparable foreign authorities for our products and product candidates;

●

our ability to enhance our products, expand our product indications and develop, acquire and commercialize additional product offerings;

our dependence on our commercial partners and independent sales agents to generate a substantial portion of our net sales;

our ability to maintain our relationships with our existing contract manufacturing customers and enter into agreements with new contract manufacturing customers, or if existing contract manufacturing customers reduce purchases of our products;

our ability to successfully ~~expand, manage~~execute or realize the anticipated benefits under our distribution arrangements with LeMaitre Vascular and ~~maintain our direct sales force;~~Sientra;

~~our ability to achieve or sustain profitability;~~

the adverse impacts of the novel strain of coronavirus disease, COVID-19 and variants thereof or any other future pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide;

Table of Contents

adverse changes in general domestic and global economic conditions and instability and disruption of credit markets, including as a result of the current COVID-19 pandemic or any other outbreak of an infectious disease, or any impacts of Russia’~~s war with Ukraine;~~

physician awareness of the distinctive characteristics, benefits, safety, clinical efficacy and cost-effectiveness of our products;

the continued and future acceptance of our products by the medical community;

●

~~our ability to continue as a going concern;~~

~~our ability to obtain regulatory approval or other marketing authorizations by the U.S. Food and Drug Administration (~~“~~FDA~~”~~) and comparable foreign authorities for our products and product candidates;~~

●

our dependence on a limited number of third-party suppliers;

●

our ability to defend against the various lawsuits related to our recall of a single lot of FiberCel and avoid a material adverse financial consequence; and

●

our ability to regain compliance with the listing standards of the Nasdaq Capital Market.

·~~our ability to obtain, maintain and adequately protect our intellectual property rights.~~

These and other important factors discussed in Part I, Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Part II, Item 1A. “Risk Factors” in this Quarterly Report, and in Part I, Item 1A. “Risk Factors” and Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2021~~2022 (the “Annual Report”) and in our other filings with the Securities and Exchange Commission (the “SEC”), each of which filings are accessible on the SEC’s website at www.sec.gov and the Investor Relations page of our website at https://investors.aziyo.com/financials/sec-filings, could cause actual results to differ materially from those indicated by the forward-looking statements made in this Quarterly Report.

Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.

You should read this Quarterly Report and the documents that we reference in this Quarterly Report completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

As used in this Quarterly Report, unless otherwise specified or the context otherwise requires, references to “we,” “us,” “our,” the “Company” and “Aziyo” refer to the operations of Aziyo Biologics, Inc. and its consolidated subsidiaries.

WEBSITE DISCLOSURE

We may use our website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investor Relations sections of its website at www.aziyo.com. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the “Email Alerts” option under the IR Resources menu of the Investor Relations of our website at www.aziyo.com. The reference to our website address does not constitute incorporation by reference of the information contained on or available through our website, and you should not consider such information to be a part of this Quarterly Report.

Table of Contents

TRADEMARKS, TRADE NAMES AND SERVICE MARKS

This Quarterly Report includes our trademarks, trade names and service marks, including, without limitation, “Aziyo®,” “CanGaroo®,” “ProxiCor®,” “Tyke®,” “VasCure®,” “ViBone®,” “OsteGro®,” “SimpliDerm®” and our logo, which are our property and are protected under applicable intellectual property laws. This Quarterly Report also contains trademarks, trade names and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks may appear in this Quarterly Report without the ®, TM and SM symbols, but such references are not intended to indicate, in any way, that we or the applicable owner forgo or will not assert, to the fullest extent permitted under applicable law, our rights or the rights of any applicable licensors to these trademarks, trade names and service marks. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.

INDUSTRY AND OTHER DATA

Unless otherwise indicated, information contained in this Quarterly Report concerning our industry and the markets in which we operate, including our general expectations, market position and market opportunity, is based on our management’s estimates and research, as well as industry and general publications and research, surveys and studies conducted by third parties. We believe the information from these third-party publications, research, surveys and studies included in this Quarterly Report is reliable. Management’s estimates are derived from publicly available information, their knowledge of our industry and their assumptions based on such information and knowledge, which we believe to be reasonable. This data involves a number of assumptions and limitations which are ~~necessarily~~ subject to a high degree of uncertainty and risk due to a variety of factors, including those described in this Quarterly Report under “Forward-Looking Statements” and Part I, Item 1A. “Risk Factors” in our Annual Report which can be found at https://investors.aziyo.com/financials/sec-filings. These and other factors could cause our future performance to differ materially from our assumptions and estimates.

Table of Contents

TABLE OF CONTENTS

		Page
FORWARD-LOOKING STATEMENTS		1
WEBSITE DISCLOSURE		2
TRADEMARKS, TRADE NAMES AND SERVICE MARKS		3
INDUSTRY AND OTHER DATA		3
PART I – FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited)
	Condensed Consolidated Balance Sheets	5
	Condensed Consolidated Statements of Operations	6
	Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)	7
	Condensed Consolidated Statements of Cash Flows	8
	Notes to the Condensed Consolidated Financial Statements	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results Of Operations	2524
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	39
Item 4.	Controls and Procedures	4039
PART II – OTHER INFORMATION
Item 1.	Legal Proceedings	40
Item 1A.	Risk Factors	4140
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	4145
Item 3.	Defaults Upon Senior Securities	4145
Item 4.	Mine Safety Disclosures	4145
Item 5.	Other Information	4145
Item 6.	Exhibits	4246
Signatures		4448

Table of Contents

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

AZIYO BIOLOGICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In Thousands, Except for Share and Per Share Data)

(UNAUDITED)


	September 30,		December 31,		June 30,		December 31,
	2022		2021		2023		2022
Assets
Current assets:
Cash	$	8,101	$	30,393	$	9,296	$	16,989
Restricted cash		—		35
Accounts receivable, net		7,159		5,996
Accounts receivable, net of credit loss reserve of $921 and $87, respectively						6,317		6,830
Inventory		10,192		9,554		9,274		10,052
Receivables of FiberCel litigation costs		17,234		—		8,876		13,813
Prepaid expenses and other current assets		970		1,450		2,363		3,015
Total current assets		43,656		47,428		36,126		50,699

Property and equipment, net		1,359		1,200		1,467		1,403
Intangible assets, net		15,918		18,466		13,370		15,069
Other assets		89		76
Operating lease right-of-use assets and other						1,366		1,670
Total assets	$	61,022	$	67,170	$	52,329	$	68,841

Liabilities and Stockholders’ Equity
Liabilities and Stockholders’ Deficit

Current liabilities:
Accounts payable	$	2,618	$	1,582	$	3,227	$	2,328
Accrued expenses		8,935		6,375
Accrued expenses and other current liabilities						11,724		10,103
Payables to tissue suppliers		3,210		2,467		2,460		3,152
Current portion of long-term debt		—		8,059
Current portion of revenue interest obligation		7,750		2,750		10,366		8,990
Revolving line of credit		—		4,763
Contingent liability for FiberCel litigation		17,643		—		14,470		17,360
Other current liabilities		12		5
Current operating lease liabilities						620		682
Total current liabilities		40,168		26,001		42,867		42,615

Long-term debt		20,000		10,410		24,927		24,260
Long-term revenue interest obligation		11,449		16,540		5,601		5,916
Long-term operating lease liabilities						711		956
Other long-term liabilities		86		698		351		127
Total liabilities		71,703		53,649		74,457		73,874

Commitments and contingencies (Note 8)

Stockholders’ equity (deficit):
Class A Common stock, $0.001 par value, 200,000,000 shares authorized as of September 30, 2022 and December 31, 2021, and 9,460,964 and 9,245,146 shares issued and outstanding, as of September 30, 2022 and December 31, 2021, respectively		9		9
Class B Common stock, $0.001 par value, 20,000,000 shares authorized, as of September 30, 2022 and December 31, 2021 and 4,313,406 issued and outstanding as of September 30, 2022 and December 31, 2021		4		4
Class A Common stock, $0.001 par value, 200,000,000 shares authorized as of June 30, 2023 and December 31, 2022, and 11,936,441 and 11,823,445 shares issued and outstanding, as of June 30, 2023 and December 31, 2022, respectively						12		12
Class B Common stock, $0.001 par value, 20,000,000 shares authorized, as of June 30, 2023 and December 31, 2022 and 4,313,406 issued and outstanding as of June 30, 2023 and December 31, 2022						4		4
Additional paid-in capital		121,854		118,599		134,439		132,939
Accumulated deficit		(132,548)		(105,091)		(156,583)		(137,988)
Total stockholders’ equity (deficit)		(10,681)		13,521
Total liabilities and stockholders' equity	$	61,022	$	67,170
Total stockholders’ deficit						(22,128)		(5,033)
Total liabilities and stockholders' deficit					$	52,329	$	68,841

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

AZIYO BIOLOGICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In Thousands, Except Share and Per Share Data)

(UNAUDITED)

Three Months Ended

Nine Months Ended

September 30,

September 30,


2022

2021

2022

2021

Net sales

$
12,389

$
11,485

$
36,522

$
36,529

Cost of goods sold

7,340

7,796

22,294

20,897

Gross profit

5,049

3,689

14,228

15,632

Sales and marketing

4,915

4,783

15,139

14,285

General and administrative

4,487

3,516

13,223

10,501

Research and development

1,966

2,289

6,855

5,890

FiberCel litigation costs

1,474

77

1,908

226

Total operating expenses

12,842

10,665

37,125

30,902

Loss from operations

(7,793)

(6,976)

(22,897)

(15,270)

Interest expense

1,302

1,328

3,721

4,034

Other (income) expense, net

803

-

803

(3,579)

Loss before provision for income taxes

(9,898)

(8,304)

(27,421)

(15,725)

Income tax expense

12

12

36

43

Net loss

$
(9,910)

$
(8,316)

$
(27,457)

$
(15,768)

Net loss per share - basic and diluted

$
(0.73)

$
(0.81)

$
(2.02)

$
(1.54)

Weighted average common shares outstanding - basic and diluted

13,660,555

10,235,350

13,618,580

10,229,974


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2023		2022		2023		2022
Net sales	$	10,296	$	12,638	$	23,346	$	24,133
Cost of goods sold		9,316		7,740		16,035		14,954
Gross profit		980		4,898		7,311		9,179
Sales and marketing		3,618		5,406		8,974		10,224
General and administrative		4,005		4,711		7,684		8,736
Research and development		1,171		2,617		2,974		4,889
FiberCel litigation costs, net		1,271		346		3,182		434
Total operating expenses		10,065		13,080		22,814		24,283
Loss from operations		(9,085)		(8,182)		(15,503)		(15,104)
Interest expense		1,524		1,204		3,068		2,419
Loss before provision for income taxes		(10,609)		(9,386)		(18,571)		(17,523)
Income tax expense		12		12		24		24
Net loss	$	(10,621)	$	(9,398)	$	(18,595)	$	(17,547)
Net loss per share - basic and diluted	$	(0.65)	$	(0.69)	$	(1.15)	$	(1.29)

Weighted average common shares outstanding - basic and diluted		16,223,919		13,620,196		16,208,905		13,597,243

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

AZIYO BIOLOGICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

(In Thousands, Except Share Amounts)

(UNAUDITED)


	Class A			Class B									Class A			Class B
	Common Stock			Common Stock									Common Stock			Common Stock
							Additional				Total								Additional				Total
	Number of			Number of			Paid-in		Accumulated		Stockholders'		Number of			Number of			Paid-in		Accumulated		Stockholders'
	Shares	Amount		Shares	Amount		Capital		Deficit		Equity (Deficit)		Shares	Amount		Shares	Amount		Capital		Deficit		Equity (Deficit)
Balance, June 30, 2022	9,306,838	$	9	4,313,406	$	4	$	121,256	$	(122,638)	$	(1,369)
Proceeds from stock option exercises	1,881		—	—		—		10		—		10
Proceeds from sale of common stock through Employee Stock Purchase Plan	32,063		—	—		—		126		—		126
Balance, March 31, 2023													11,876,792	$	12	4,313,406	$	4	$	133,771	$	(145,962)	$	(12,175)
Vesting of restricted stock units, net of shares withheld and taxes paid	120,182		—	—		—		(395)		—		(395)	59,649		—	—		—		(19)		—		(19)
Issuance of warrants in connection with debt financing	—		—	—		—		560		—		560
Stock-based compensation	—		—	—		—		297		—		297	—		—	—		—		687		—		687
Net loss	—		—	—		—		—		(9,910)		(9,910)	—		—	—		—		—		(10,621)		(10,621)
Balance, September 30, 2022	9,460,964	$	9	4,313,406	$	4	$	121,854	$	(132,548)	$	(10,681)
Balance, June 30, 2023													11,936,441	$	12	4,313,406	$	4	$	134,439	$	(156,583)	$	(22,128)

Balance, June 30, 2021	7,095,265	$	7	3,134,162	$	3	$	102,668	$	(87,711)	$	14,967
Proceeds from sale of common stock through Employee Stock Purchase Plan	27,244		—	—		—		208		—		208
Balance, March 31, 2022													9,306,738	$	9	4,313,406	$	4	$	119,786	$	(113,240)	$	6,559
Vesting of restricted stock units													100		—	—		—		—		—		—
Stock-based compensation	—		—	—		—		1,000		—		1,000	—		—	—		—		1,470		—		1,470
Net loss	—		—	—		—		—		(8,316)		(8,316)	—		—	—		—		—		(9,398)		(9,398)
Balance, September 30, 2021	7,122,509	$	7	3,134,162	$	3	$	103,876	$	(96,027)	$	7,859
Balance, June 30, 2022													9,306,838	$	9	4,313,406	$	4	$	121,256	$	(122,638)	$	(1,369)

	Class A			Class B									Class A			Class B
	Common Stock			Common Stock									Common Stock			Common Stock
							Additional				Total								Additional				Total
	Number of			Number of			Paid-in		Accumulated		Stockholders'		Number of			Number of			Paid-in		Accumulated		Stockholders'
	Shares	Amount		Shares	Amount		Capital		Deficit		Equity (Deficit)		Shares	Amount		Shares	Amount		Capital		Deficit		Equity (Deficit)
Balance, December 31, 2022													11,823,445	$	12	4,313,406	$	4	$	132,939	$	(137,988)	$	(5,033)
Proceeds from sale of common stock through Employee Stock Purchase Plan													41,277		—	—		—		148		—		148
Vesting of restricted stock units, net of shares withheld and taxes paid													71,719		—	—		—		(19)		—		(19)
Stock-based compensation													—		—	—		—		1,371		—		1,371
Net loss													—		—	—		—		—		(18,595)		(18,595)
Balance, June 30, 2023													11,936,441	$	12	4,313,406	$	4	$	134,439	$	(156,583)	$	(22,128)

Balance, December 31, 2021	9,245,146	$	9	4,313,406	$	4	$	118,599	$	(105,091)	$	13,521	9,245,146	$	9	4,313,406	$	4	$	118,599	$	(105,091)	$	13,521
Proceeds from stock option exercises	1,881		—	—		—		10		—		10
Additional issuance costs in connection with Private Placement	—		—	—		—		(110)		—		(110)	—		—	—		—		(110)		—		(110)
Proceeds from sale of common stock through Employee Stock Purchase Plan	74,408		—	—		—		317		—		317	42,345		—	—		—		192		—		192
Vesting of restricted stock units, net of shares withheld and taxes paid	139,529		—	—		—		(395)		—		(395)
Issuance of warrants in connection with debt financing	—		—	—		—		560		—		560
Vesting of restricted stock units													19,347		—	—		—		—		—		—
Stock-based compensation	—		—	—		—		2,873		—		2,873	—		—	—		—		2,575		—		2,575
Net loss	—		—	—		—		—		(27,457)		(27,457)	—		—	—		—		—		(17,547)		(17,547)
Balance, September 30, 2022	9,460,964	$	9	4,313,406	$	4	$	121,854	$	(132,548)	$	(10,681)

Balance, December 31, 2020	7,091,960	$	7	3,134,162	$	3	$	101,080	$	(80,259)	$	20,831
Proceeds from stock option exercises	3,305		—	—		—		26		—		26
Proceeds from sale of common stock through Employee Stock Purchase Plan	27,244		—	—		—		208		—		208
Stock-based compensation	—		—	—		—		2,562		—		2,562
Net loss	—		—	—		—		—		(15,768)		(15,768)
Balance, September 30, 2021	7,122,509	$	7	3,134,162	$	3	$	103,876	$	(96,027)	$	7,859
Balance, June 30, 2022													9,306,838	$	9	4,313,406	$	4	$	121,256	$	(122,638)	$	(1,369)

The accompanying notes are an integral part of these condensed consolidated financial statements

Table of Contents

AZIYO BIOLOGICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In Thousands)

(UNAUDITED)


	Nine Months Ended				Six Months Ended
	September 30,				June 30,
	2022		2021		2023		2022
Net loss	$	(27,457)	$	(15,768)	$	(18,595)	$	(17,547)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		2,796		2,797		1,901		1,863
(Gain) loss on extinguishment of debt		311		(3,029)
Amortization of deferred financing costs and debt discount		63		91		107		29
Interest expense recorded as additional revenue interest obligation		1,983		1,987
Interest expense recorded as additional revenue interest obligation or long-term debt						1,619		1,319
Stock-based compensation		2,873		2,562		1,371		2,575
Bad debt expense						834		—
Losses associated with viable bone matrix recall and market withdrawal						1,984		—
Changes in operating assets and liabilities:
Accounts receivable		(1,163)		1,647		(321)		(650)
Inventory		(638)		285		(1,206)		(145)
Receivables of FiberCel litigation costs		(17,234)		—		4,937		—
Prepaid expenses and other		467		1,615		652		(378)
Accounts payable and accrued expenses		4,029		(1,456)
Accounts payable and accrued expenses and other current liabilities						2,520		1,324
Obligations to tissue suppliers		743		419		(692)		732
Contingent liability for FiberCel litigation		17,643		—		(2,890)		—
Deferred revenue and other liabilities		(605)		(209)		224		204
Net cash used in operating activities		(16,189)		(9,059)		(7,555)		(10,674)
INVESTING ACTIVITIES:
Expenditures for property, plant and equipment		(406)		(344)		(267)		(289)
Net cash used in investing activities		(406)		(344)		(267)		(289)
FINANCING ACTIVITIES:
Additional issuance costs in connection with Private Placement		(110)		—		—		(110)
Net borrowings (repayments) under revolving line of credit		(4,763)		(4,558)		—		1,689
Proceeds from stock option exercises		10		26
Proceeds from long-term debt		21,000		—
Deferred financing costs		(468)		—
Repayments of long-term debt		(18,615)		(1,111)		—		(3,333)
Costs related to the extinguishment of debt		(633)		—
Payments on revenue interest obligation		(2,075)		(2,068)		—		(1,392)
Payments for taxes upon vesting of restricted stock units		(395)		—		(19)		—
Proceeds from sales of common stock through Employee Stock Purchase Plan		317		208		148		192
Net cash used in financing activities		(5,732)		(7,503)
Net cash provided by (used in) financing activities						129		(2,954)

Net decrease in cash and restricted cash		(22,327)		(16,906)		(7,693)		(13,917)

Cash and restricted cash, beginning of period		30,428		39,532		16,989		30,428
Cash and restricted cash, end of period	$	8,101	$	22,626	$	9,296	$	16,511

Supplemental Cash Flow and Non-Cash Financing Activities Disclosures:
Cash paid for interest	$	5,047	$	3,788	$	1,100	$	1,162
Fair value of warrants issued	$	560	$	—
Forgiveness of SBA PPP loan	$	-	$	3,029

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

AZIYO BIOLOGICS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Organization and Description of Business

Aziyo Biologics, Inc. (together with its consolidated subsidiaries, ~~"Aziyo”~~“Aziyo” or the “Company”) is a regenerative medicine company, with a focus on patients receiving implantable medical devices. The Company has developed a portfolio of regenerative products using both human and porcine tissue that are designed to be as close to natural biological material as possible. Aziyo’s portfolio of ~~core~~ products ~~spans~~span the ~~implantable electronic devices/cardiovascular-related market, the orthopedic/spinal repair market~~device protection, women’s health, orthobiologics and ~~the soft tissue reconstruction market (“Core Products”).~~cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. The Company also sells human tissue products under contract manufacturing and certain other arrangements ~~(“Non-Core Products”)~~ with corporate customers.

Note 2. Summary of Significant Accounting Policies

Basis of Presentation and Liquidity

The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s consolidated financial statements and accompanying notes included in the Company's annual report on Form 10-K (“Annual Report”) for the fiscal year ended December 31, ~~2021.~~2022. The financial information as of ~~September~~June 30, ~~2022~~2023 and for the three and ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 and ~~2021~~2022 is unaudited, but in the opinion of management, all adjustments considered necessary for a fair statement of the results for these interim periods have been included. The condensed consolidated balance sheet data as of December 31, ~~2021~~2022 was derived from audited financial statements but does not include all disclosures required by GAAP. The results of the Company’s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or any future year or period.

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in ~~consolidation.~~ consolidaton.

In accordance with Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. For the ~~nine~~six months ended ~~September~~June 30, ~~2022,~~2023, the Company incurred a net loss of ~~$27.5~~$18.6 million, and as of ~~September~~June 30, ~~2022,~~2023, the Company had an accumulated deficit of ~~$132.5~~$156.6 million. In addition, during the ~~nine~~six months ended ~~September~~June 30, ~~2022,~~2023, the Company used ~~$16.2 million and $5.7~~$7.6 million of cash in operating ~~and financing~~ activities, ~~respectively,~~ and expects to continue to incur cash outflows ~~for~~during the remainder of ~~the year.~~2023. Because of the numerous risks and uncertainties associated with the Company’s commercialization and development efforts, the Company is unable to predict when it will become profitable, and it may never become profitable. The Company’s inability to achieve and then maintain profitability would negatively affect its business, financial condition, results of operations and cash flows.

In order to mitigate the current and potential future liquidity issues caused by the matters noted above, the Company may seek to raise capital through the issuance of common stock or debt, restructure its Revenue Interest Obligation (as such term is defined, and further described, in Note 7), or pursue asset sale or ~~licensing~~other transactions. However, such transactions may not be successful and the Company may not be able to raise additional equity or debt, restructure its Revenue Interest Obligation, or sell or license assets on acceptable terms, or at all. As such, based on its current operating plans, the Company believes there is uncertainty as to whether its future cash flows along with its existing cash, ~~potential availability under the SWK Loan Facility (described in Note 6),~~ issuances of additional equity and cash

~~Table of Contents~~

generated from expected future sales will be sufficient to meet the Company’s anticipated operating needs through twelve months from the financial statement issuance date. Due to these factors, there

Table of Contents

is substantial doubt about the Company’s ability to continue as a going concern within one year after the issuance of the financial statements.

The accompanying ~~condensed~~ consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. That is, the accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business.

Reclassifications

Certain reclassifications have been made to prior year amounts to conform to current year financial statement presentation. The reclassifications relate to the separate presentation of prior year costs related to the FiberCel ~~Litigation (see Note 8 for further discussion).~~Litigation. Such costs were formerly shown as a component of general and administrative expenses in the accompanying ~~condensed~~ consolidated statements of operations. Additionally, the Company determined in its fourth quarter of 2022 that its operating and reportable segments are consistent with its major product groupings – Device Protection, Women’s Health, Orthobiologics and Cardiovascular. Segment results for the three and six months ended June 30, 2022, have been recasted to conform to the new segmentpresentation. Refer to the Segment Information in Note 10.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions relating to ~~inventory,~~inventories, receivables, long-lived assets, the valuation of stock-based awards, the valuation of the ~~Revenue Interest Obligation~~revenue interest obligation, the contingent liability for the FiberCel Litigation and deferred income taxes are made at the end of each financial reporting period by management. Management continually re-evaluates its estimates, judgments and assumptions, and management's evaluation could change. Actual results could differ from those estimates.

~~Impact of COVID-19~~

The Company continues to closely monitor the impact of the COVID-19 pandemic and its variants on its business. In March 2020, the World Health Organization declared COVID-19 a global pandemic and recommended various containment and mitigation measures worldwide. Since that time, the number of procedures performed using the Company's products has intermittently decreased, as governmental authorities in the United States have recommended, and in certain cases required, that elective, specialty and other non-emergency procedures and appointments be suspended or canceled in order to avoid patient exposure to medical environments and the risk of potential infection with COVID-19, and to focus limited resources and personnel capacity on the treatment of COVID-19 patients. As a result, beginning in March 2020, a significant number of procedures using the Company's products have intermittently been postponed or cancelled, which has negatively impacted sales of its products. These measures and challenges will likely continue for the duration of the pandemic, which is uncertain, and may reduce the Company's net sales in the future and negatively impact its business, financial condition and results of operations while the pandemic continues.

Net Loss per Share Attributable to Common Stockholders

Our common stock has a dual class structure, consisting of Class A common stock, $0.001 par value per share (the “Class A common ~~stock)~~stock”) and Class B common stock, $0.001 par value per share (the “Class B common ~~stock)~~stock”). Other than voting rights, the Class B common stock has the same rights as the Class A common stock, and therefore both are treated as the same class of stock for purposes of the earnings per share calculation. Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average shares outstanding during the period. For purposes of the diluted net income (loss) per share attributable to common stockholders calculation, stock options, ~~and~~ restricted stock units (“RSUs”) and warrants are considered to be common stock equivalents. All common stock equivalents have been excluded from the calculation of diluted net loss per share attributable to common stockholders, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share were the same for both periods presented.

~~Table of Contents~~

Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:

Level 1 - Valuations based on quoted prices for identical assets and liabilities in active markets.

Level 2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.

Table of Contents

Level 3 - Valuations based on unobservable inputs reflecting the Company’s own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

The estimated fair value of financial instruments disclosed in the financial statements has been determined by using available market information and appropriate valuation methodologies. The carrying value of all current assets and current liabilities approximates fair value because of their short-term nature.

Cash ~~and Restricted Cash~~

The Company maintains its cash balances at banks and financial institutions. The balances are insured up to the legal limit. The Company maintains cash balances that may, at times, exceed this insured limit.

Under the provisions of the Company’s former revolving credit facility, the MidCap Credit Facility (as such term is defined, and further described in Note 6), the Company had a lockbox arrangement with the banking institution whereby daily lockbox receipts were contractually utilized to pay down outstanding balances on the MidCap Credit Facility debt. Lockbox receipts that had not yet been applied to the MidCap Credit Facility were classified as restricted cash in the accompanying condensed consolidated balance sheets. The following table provides a reconciliation of cash and restricted cash included in the condensed consolidated balance sheets to the amounts included in the statements of cash flows (in thousands).

September 30,


2022

2021
Cash

$
8,101

$
22,543
Restricted cash

—

83
Total cash and restricted cash shown in statements of cash flows

$
8,101

$
22,626

Accounts Receivable and Allowances

Accounts receivable in the accompanying balance sheets are presented net of allowances for ~~doubtful accounts and other credits.~~credit losses. The Company grants credit to customers in the normal course of business, but generally does not require collateral or any other security to support its receivables.

The Company evaluates the collectability of accounts receivable based on a combination of factors. In circumstances where a specific customer is unable to meet its financial obligations to the Company, a provision to the allowance for doubtful accounts is recorded to reduce the net recognized receivable to the amount that is reasonably expected to be collected. For all other customers, a provision to the allowance for ~~doubtful accounts~~credit losses is recorded based on factors including the length of time the receivables are past due, the current business environment and the Company’s historical experience. Provisions to the allowance for doubtful accounts are recorded to general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered.

~~Table of Contents~~

Inventory

Inventory, consisting of purchased materials, direct labor and manufacturing overhead, is stated at the lower of cost or net realizable value, with cost determined generally using the average cost method. Inventory write-downs for unprocessed and certain processed donor tissue are recorded based on the estimated amount of inventory that will not pass the quality control process based on historical data. At each balance sheet date, the Company also evaluates inventory for excess quantities, obsolescence or shelf life expiration. This evaluation includes analysis of the Company’s current and future strategic plans, historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions and a review of the shelf life expiration dates for products. To the extent that management determines there is excess or obsolete inventory or quantities with a shelf life that is too near its expiration for the Company to reasonably expect that it can sell those products prior to their expiration, the Company adjusts the carrying value to estimated net realizable value.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed on the straight-line method over the following estimated useful lives of the assets:


Processing and research equipment		5 to 10 years
Office equipment and furniture		3 to 5 years
Computer hardware and software		3 years

Leasehold improvements are amortized on the straight-line method over the shorter of the lease term or the estimated useful life of the asset.

Repairs and maintenance costs are expensed as incurred.

Table of Contents

Leases

In February 2016, the FASB issued ASU No 2016-02 “Leases” to increase the transparency and comparability about leases among entities. ASU 2016-02 and certain additional ASUs are now codified as Accounting Standards Codification Standard 842 - “Leases” (“ASC 842”). ASC 842 supersedes the lease accounting guidance in Accounting Standards Codification 840 “Leases” (“ASC 840”) and requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. The Company determines if an arrangement contains a lease at inception. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from that lease. For leases with a term greater than 12 months, ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The lease term includes the option to extend the lease when it is reasonably certain the Company will exercise that option. When available, the Company uses the rate implicit in the lease to discount lease payments to present value. In the case the implicit rate is not available, the Company uses its incremental borrowing rate based on information available at the lease commencement date, including publicly available data for instruments with similar characteristics, to determine the present value of lease payments. The Company combines lease and non-lease elements for office leases.

Long-Lived Assets

Purchased intangible assets with finite lives are carried at acquired fair value, less accumulated amortization. Amortization is computed over the estimated useful lives of the respective assets.

The Company periodically evaluates the period of depreciation or amortization for long-lived assets to determine whether current circumstances warrant revised estimates of useful lives. The Company reviews its property and equipment and intangible assets for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment exists when the carrying value of the company’s asset exceeds the related estimated undiscounted future cash flows expected to be derived from the asset. If impairment exists, the carrying value of that asset is adjusted to its fair value. A discounted cash flow analysis is used to estimate an asset’s fair value, using assumptions that market participants would apply. The results of impairment tests are subject to management’s estimates and assumptions of projected cash flows and operating results. Changes in assumptions or market conditions could result in a change in estimated future cash flows and could result in a lower fair value and therefore an impairment, which could impact reported results. There were no impairment losses for the three and ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 or ~~2021.~~2022.

Revenue Recognition

The Company’s revenue is generated from contracts with customers in accordance with ~~Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”)~~ASC 606. The core principle of ASC 606 is that the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The ASC 606 revenue recognition model consists of the following five steps: (1) identify the contracts with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.

~~Table of Contents~~

As noted above, the Company enters into contracts to primarily (i) sell and distribute products to healthcare providers or commercial partners, or (ii) produce and sell products under contract manufacturing arrangements with corporate customers, ~~and in all such cases, customers~~which are billed under ship and bill contract terms. Revenue is recognized when the Company has met its performance obligations pursuant to its contracts with its customers in an amount that the Company expects to be entitled to in exchange for the transfer of control of the products to the Company’s customers. For all product sales, the Company has no further performance obligations and revenue is recognized at the point control transfers which occurs either when: ~~(i)~~i) the product is shipped via common carrier; or ~~(ii)~~ii) the product is delivered to the customer or distributor, in accordance with the terms of the agreement.

Table of Contents

A portion of the Company’s product revenue is generated from consigned inventory maintained at hospitals and from inventory physically held by distributors and direct sales representatives. For these types of ~~product~~products sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized.

The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in sales and marketing costs.

Contracts with customers state the final terms of the sale, including the description, quantity, and price of each implant distributed. The payment terms and conditions in the Company’s contracts vary; however, as a common business practice, payment terms are typically due in full within 30 to 60 days of delivery. The Company, at times, extends volume discounts to customers.

The Company permits returns of its products in accordance with the terms of contractual agreements with customers. Allowances for returns are provided based upon analysis of the Company’s historical patterns of returns matched against the revenues from which they originated. The Company records estimated returns as a reduction of revenue in the same period revenue is recognized.

~~Deferred Rent~~

The Company recognizes rent expense by the straight-line method over the lease term. Funds received from the lessor used to reimburse the Company for the cost of leasehold improvements are recorded as a deferred credit resulting from a lease incentive and are amortized over the lease term as a reduction of rent expense.

Stock-Based Compensation Plans

The Company accounts for its stock-based compensation plans in accordance with FASB ASC 718, Accounting for Stock Compensation. FASB ASC 718 requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors, including employee stock options and restricted stock. Stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense on a straight-line basis over the requisite service period of the entire award.

Research and Development Costs

Research and development costs, which include mainly salaries, outside services and supplies, are expensed as incurred.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. At ~~September~~June 30, ~~2022,~~2023, the Company maintained ~~$7.8~~$9.3 million in bank deposit accounts that are in excess of the $0.25 million insurance provided by the Federal Deposit Insurance Corporation in one federally insured financial institution. Market conditions can impact the viability of these institutions. In the event of failure of any of the financial institutions where we maintain our cash, the Company could lose its deposits in excess of the federally insured or protected amounts and there can be no assurance that we will be able to access uninsured funds in a timely manner or at all. The Company has not experienced any losses in such accounts.

~~Table of Contents~~

~~Significant Customers~~

~~The Company sells~~On June 19, 2023, Surgalign Holdings, Inc. (“Surgalign”) and certain of its ~~products~~direct and indirect subsidiaries commenced voluntary proceedings under ~~large contract manufacturing or distribution arrangements.~~chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. The ~~following table presents~~ percentage of the Company’s total revenues derived from Surgalign was 10% during the three and six months ended June 30, 2023 and 2022. As of June 30, 2023, the Company’s ~~largest customers as well as their respective percentage~~gross accounts receivable from Surgalign totaled $1.1 million, of ~~total accounts receivable:~~

Three Months Ended

Nine Months Ended

September 30,

September 30,

2022

2021

2022

2021

Percent of revenues derived from:

ACE Surgical Supply

11%

9%

10%

4%

Surgalign Holdings

11%

9%

11%

10%

Medtronic Sofamor Danek USA

-

3%

-

13%

September 30,

December 31,

2022

2021

Percent of accounts receivable derived from:

ACE Surgical Supply

5%

3%

Surgalign Holdings

13%

12%

Medtronic Sofamor Danek USA

-

-

which $0.8 million has been reserved at June 30, 2023 due to the uncertainty of collection.

Comprehensive Income (Loss)

Comprehensive income (loss) comprises net income (loss) and other changes in equity that are excluded from net income (loss). For the three and ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 and ~~2021,~~2022, the Company’s net loss equaled its comprehensive loss and accordingly, no additional disclosure is presented.

Table of Contents

Income Taxes

The Company uses the asset and liability method of accounting for income taxes. Deferred income taxes are recorded to reflect the tax consequences on future years for differences between the tax basis of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to amounts that are more likely than not to be realized.

The Company is subject to income taxes in the federal and state jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. In accordance with the authoritative guidance on accounting for uncertainty in income taxes, the Company recognizes tax liabilities for uncertain tax positions when it is more likely than not that a tax position will not be sustained upon examination and settlement with various taxing authorities. Liabilities for uncertain tax positions are measured based upon the largest amount of benefit that is more likely than not (greater than 50%) of being realized upon settlement. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense.

Note 3. Recently Issued Accounting Standards

In ~~November 2019,~~June 2016, the FASB issued ASU ~~2019-10, “Financial~~2016-13, Financial Instruments -– Credit Losses (Topic 326)~~, Derivative~~: Disclosure Framework – Measurement of Credit Losses on Financial Instruments, which requires financial assets measured at amortized cost, including trade receivables, be presented net of the amount expected to be collected. The measurement of all expected credit losses is based on relevant information about the credit quality of customers, past events, including historical experience, and ~~Hedging (Topic 815),~~reasonable and ~~Leases (Topic 842), Effective Dates.” The~~supportable forecasts that affect the collectability of the reported amount. In October 2019, the FASB ~~deferred~~voted to approve a proposal to defer the effective ~~dates~~date of ASC 2016-13 for certain entities, including emerging growth companies that take advantage of the ~~new credit losses standard for all entities except filers with the Securities and Exchange Commission (the “SEC”) that are not smaller reporting companies (“SRCs”)~~extended transition period, to fiscal years beginning after December 15, ~~2022, including interim periods within those fiscal years. The FASB also aligned~~2022. This ASU was effective for the ~~effective dates of ASU 2017-04~~Company beginning on ~~goodwill impairment with the new effective dates of the credit losses standard. The FASB deferred the effective dates of its new standards on hedging~~January 1, 2023 and ~~leases for entities that are~~did not public business entities (“PBEs”) (and for leases, for entities that are not non-for-profit (“NFP”) entities that have issues, or are conduit bond obligors for, certain securities; and are not employee benefit plans (“EBPs”) that file or furnish financial statements with or to the SEC) to fiscal years beginning after December 15, 2020, and interim periods in the following year. The FASB is also reconsidering its philosophy on establishing effective dates

~~Table of Contents~~

for major standards for private companies, NFPs, EBPs and smaller public companies. The FASB has developed a two-bucket approach that would give these entities more time to implement major new standards. The Company is evaluating this standard to determine if adoption will have a material impact on our condensed consolidated Financial Statements. The Company adopted this ASU using the ~~Company’s consolidated financial statements.~~

~~In February 2016,~~modified retrospective transition method. Under this transition method, the ~~FASB issued ASU 2016-02, Leases.~~new standard is applied from January 1, 2023 without restatement of comparative period amounts. The ~~standard requires that lessees recognize a right-of-use asset and a lease liability for virtually all~~impact of ~~their leases (other than leases that meet the definition of a short-term lease). The liability will be equal~~transitioning to the ~~present value~~new standard was immaterial and no adjustment was recorded to retained earnings for the cumulative effect of ~~lease payments. The asset will be based~~adopting this ASU on ~~the liability subject to certain adjustments. For income statement purposes, the FASB retained a dual model, requiring leases~~January 1, 2023. Results for reporting periods beginning after January 1, 2023 are presented under Topic 326 while prior period amounts continue to be ~~classified as either operating or finance. Operating leases will result~~reported in straight-line expense (similar to current operating leases) while finance leases will result in a front-loaded expense pattern (similar to current capital leases). In November 2019, the FASB issued 2019-10 which extended the adoption of ASU 2016-02 for the Company to be effective for periods ending after December 15, 2022. While early adoption is permitted, the Company will adopt the standard in the fourth quarter of 2022 for the full 2022 year, and expects to recognize right-of-use assets and ~~lease liabilities~~ ~~for operating leases of approximately $2.4 million.~~accordance with previously applicable GAAP.

Note 4. Stock-Based Compensation

In 2015, the Company established the Aziyo Biologics, Inc. 2015 Stock Option/Stock Issuance Plan, as amended (the “2015 Plan”) which provided for the granting of incentive and non-qualified stock options to employees, directors and consultants of the Company. On October 7, 2020, ~~in connection with the Company’s initial public offering (“IPO”),~~ the Company adopted the Aziyo Biologics, Inc. 2020 Incentive Award Plan, which was amended and restated on June 8, 2023 (the “2020 Plan”)~~, which~~. The 2020 Plan authorizes the grant of incentive and non-qualified stock options, restricted stock, restricted stock units and stock appreciation rights to employees, directors and consultants. Shares of Class A common stock totaling ~~1,636,000 were initially~~3,636,000 have been reserved for issuance ~~pursuant to~~under the 2020 Plan. In addition, the shares reserved for issuance under the 2020 Plan ~~will~~ also include shares reserved but not issued under the 2015 Plan as well as an annual increase as set forth in the 2020 Plan. As of ~~September~~June 30, ~~2022,~~2023, the Company had ~~756,809~~3,308,997 shares of Class A common stock available for issuance under the 2020 Plan.

On June 21, 2022, C. Randal Mills, Ph.D., a member of the Board of Directors (the “Board”) of the Company, was appointed as the Company’s Interim President and Chief Executive Officer, succeeding Ronald Lloyd, who stepped down as the Company’s President and Chief Executive Officer and as a member of the Board. In connection with his appointment as the Interim President and Chief Executive Officer, Dr. Mills and the Company entered into an employment agreement for an initial term of 90 days (such period, the “Interim Period”). On August 9, 2022, Dr. Mills was appointed to the role of President and Chief Executive Officer of the Company, thereby ending the Interim Period, and his employment agreement was extended pursuant to the terms thereof.

In accordance with the terms of his employment agreement, Dr. Mills (1) received a stock option award to purchase 456,278 shares of Class A common stock of the Company (the “Option Grant”) on June 21, 2022; three-fifths of such Option Grant is subject to time-based vesting (the ~~“Time-Based~~

Table of Contents

“Time-Based Options”) and two-fifths of such Option Grant is subject to performance-based vesting (the “Performance Based Options”) and (2) is eligible to receive 224,734 restricted stock units (the “RSU Grant”); three-fifths of such RSU Grant is subject to time-based vesting (the “Time-Based RSUs”) and two-fifths of such RSU Grant is subject to performance-based vesting (the “Performance-Based RSUs”). One-third of the Time-Based Options vested on August 9, ~~202~~20222 (end of the Interim Period), and two-thirds of the Time-Based Options vest over a four-year vesting schedule with 25% vesting on the first anniversary of June 21, 2022 and the remaining portion vesting in twelve equal quarterly installments. One-third of the Time-Based RSUs vest on the grant date, and two-thirds of the Time-Based RSUs vest over a four-year vesting schedule in equal annual installments. The Performance-Based Options and Performance-Based RSUs each vest in equal installments upon the achievement of certain share price thresholds for twenty consecutive days of trading at each respective threshold. Pursuant to the terms of the employment agreement, all of these awards were deemed granted on June 21, 2022, for purposes of and in accordance with ASC 718, Accounting for Stock Based Compensation; however, the RSUs ~~had~~were not ~~been~~ legally granted ~~as of September 30, 2022. It is anticipated that such RSUs will be legally granted prior to December 31, 2022,~~until April 2023 and the vested shares underlying the award ~~will be~~were not deemed outstanding ~~as of~~until such time.

~~Table of Contents~~

In connection with his resignation as President and Chief Executive Officer, Mr. Lloyd and the Company entered into a separation agreement, pursuant to which Mr. Lloyd remained a full-time, non-officer employee of the Company through September 30, 2022 to assist with the transition of his duties to his successor. On September 30, 2022, Mr. Lloyd received: (i) cash severance in an amount equal to his base salary for a period of 12 months and 100% of his annual target bonus and (ii) the COBRA benefits, during the 12-month period following September 30, 2022. The Company recognized Mr. Lloyd’s severance costs totaling approximately $0.6 million over the period from June 21, 2022 through September 30, 2022, and as of September 30, 2022, all such expenses were included in Accrued Expenses in the accompanying condensed consolidated balance sheets.

Stock Options

The Company’s policy is to grant stock options at an exercise price equal to 100% of the market value of a share of Class A common stock at closing on the date of the grant. The Company’s stock options generally have contractual terms of ~~seven~~ to ten years and ~~generally~~ vest over a four-year period from the date of grant.

A summary of stock option activity under the Company’s 2015 Plan and 2020 Plan for the ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 is as follows:


				Weighted-							Weighted-
				Average							Average
		Weighted-		Remaining		Aggregate			Weighted-		Remaining		Aggregate
		Average		Contractual		Intrinsic			Average		Contractual		Intrinsic
		Exercise		Term		Value			Exercise		Term		Value
	Number of Shares	Price		(years)		(in thousands)		Number of Shares	Price		(years)		(in thousands)
Outstanding, December 31, 2021	1,386,811	$	13.28		7.8	$	179
Outstanding, December 31, 2022								1,864,739	$	9.41		7.5	$	8
Granted	1,075,858	$	5.77					157,500	$	2.64
Exercised	(1,881)	$	5.58					—	$	—
Forfeited	(705,341)	$	10.83					(355,690)	$	10.00
Outstanding, September 30, 2022	1,755,447	$	9.68		7.2	$	1,329
Vested and exercisable, September 30, 2022	688,632	$	10.40		4.2	$	419
Outstanding, June 30, 2023								1,666,549	$	8.64		8.3	$	-
Vested and exercisable, June 30, 2023								704,485	$	9.85		7.6	$	-

The weighted average grant date fair value of options granted during the ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 was ~~$3.15.~~$1.63. As of ~~September~~June 30, ~~2022,~~2023, there was approximately ~~$4.1~~$3.1 million of total unrecognized compensation expense related to unvested stock options. These costs are expected to be recognized over a weighted-average period of ~~2.5~~2.2 years.

The Company uses the Black-Scholes model to value its time-based stock option grants and expenses the related compensation cost using the straight-line method over the vesting period. The fair value of stock options is determined on the grant date using assumptions for the estimated fair value of the underlying common stock, expected term, expected volatility, dividend yield, and the risk-free interest rate. Before the completion of the Company’s IPO, the Board determined the fair value of common stock considering the state of the business, input from management, third party valuations and other considerations. The Company uses the simplified method for estimating the expected term used to determine the fair value of options. The expected volatility of the Class A common stock is primarily based on the historical volatility of comparable companies in the industry whose share prices are publicly available. The Company uses a zero-dividend yield assumption as the Company has not paid dividends since inception nor does it anticipate paying dividends in the future. The risk-free interest rate approximates recent U.S. Treasury note auction results with a similar life to that of the option. The period expense is then determined based on the valuation of the options, and is recognized on a straight-line basis over the requisite service period for the entire award.

1615

Table of Contents

The following weighted-average assumptions were used to determine the fair value of options granted during the ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 and ~~2021:~~2022:


	Nine Months Ended				Six Months Ended
	September 30,				June 30,
	2022		2021		2023		2022
Expected term (years)	6.2		6.0		6.0		6.2
Risk-free interest rate	2.0	%	1.0	%	3.9	%	2.0	%
Volatility factor	53	%	64	%	63.8	%	53.0	%
Dividend yield	—		—		—		—

For the Performance-Based Options with a market condition granted as described above, the Company ~~accounted for the awards as market condition awards and~~ used an option pricing model, the Monte Carlo model, to determine the fair value of the respective equity instruments and an expense recognition term of approximately three years.

Restricted Stock Units

Restricted stock units (“RSUs”) represent rights to receive common shares at a future date. There is no exercise price and no monetary payment is required for receipt of restricted stock units or the shares issued in settlement of the award. The Company’s RSUs generally vest over a three to four year period from the date of grant.

A summary of the RSU activity under the Company’s 2020 Plan for the ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 is as follows:


		Weighted-			Weighted-
		Average			Average
	Number of Shares	Grant Date		Number of Shares	Grant Date
	Underlying RSUs	Fair Value		Underlying RSUs	Fair Value
Unvested, December 31, 2021	235,985	$	15.98
Unvested, December 31, 2022				372,307	$	5.90
Granted	586,083	$	4.08	—	$	—
Vested	(238,142)	$	6.64	(34,994)	$	9.23
Forfeited	(210,594)	$	11.42	(33,378)	$	4.45
Unvested, September 30, 2022	373,332	$	5.89
Unvested, June 30, 2023				303,935	$	5.60

~~The total fair value of~~For the ~~RSUs granted during the nine months ended September 30, 2022 was $2.4 million.~~

~~During the nine months ended September 30, 2022, the Company granted 289,282~~ Performance-Based ~~RSUs. All such~~ RSUs, including those granted to Dr. Mills ~~and~~as described above, ~~vest only if or when~~ the ~~Company’s Class A common stock closing price is at or exceeds a defined share price for a defined period of time. As such, all of these awards have been~~Company accounted for the awards as market condition ~~awards. Given the nature of these market condition arrangements,~~awards and used an option pricing model, the Monte Carlo model, ~~was used~~ to determine the fair value of ~~these RSUs as well as~~ the respective equity instruments and an expense recognition term of two to three years using the graded vesting method.

As of ~~September~~June 30, ~~2022, $1.7~~2023, $0.9 million of unrecognized compensation costs related to RSUs is expected to be recognized over a weighted average period of approximately two years.

Employee Stock Purchase Plan

The Company makes shares of its Class A common stock available for purchase under the Aziyo Biologics, Inc. 2020 Employee Stock Purchase Plan (the “ESPP”). The ESPP provides for separate six-month offering periods that begin in March and September of each year. Under the ESPP, employees may purchase a limited number of shares of Aziyo Class A common stock at 85% of the fair market value on either the first day of the offering period or the purchase date, whichever is lower. The ESPP is considered compensatory for purposes of stock-based compensation expense. The number of shares reserved under the ESPP will automatically increase on the first day of each fiscal year through January 1, 2030, in an amount as set forth in the ESPP. As of ~~September~~June 30, ~~2022,~~2023, the total shares of Class A common stock authorized for issuance under the ESPP was 542,365, of which 399,436 remained available for future issuance. During the three and six months ended June 30, 2023, 41,277 shares of Class A common stock were issued under the ESPP.

1716

Table of Contents

authorized for issuance under the ESPP was 380,997, of which 279,345 remained available for future issuance. During the nine months ended September 30, 2022, 74,408 shares of Class A common stock were issued under the ESPP.

Stock-Based Compensation Expense

Stock-based compensation expense recognized during the three and ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 and ~~2021~~2022 was comprised of the following (in thousands):


	Three Months Ended				Nine Months Ended				Three Months Ended				Six Months Ended
	September 30,				September 30,				June 30,				June 30,
	2022		2021		2022		2021		2023		2022		2023		2022
Sales and marketing	$	343	$	185	$	841	$	488	$	159	$	302	$	303	$	498
General and administrative		(120)		622		1,465		1,557		441		903		895		1,585
Research and development		8		139		432		391		45		247		91		424
Cost of goods sold		66		53		135		126		42		18		82		68
Total stock-based compensation expense	$	297	$	999	$	2,873	$	2,562	$	687	$	1,470	$	1,371	$	2,575

Note 5. Inventory

Inventory was comprised of the following (in thousands):


	September 30,		December 31,		June 30,		December 31,
	2022		2021		2023		2022
Raw materials	$	2,055	$	1,880	$	1,489	$	1,716
Work in process		617		834		937		623
Finished goods		7,520		6,840		6,848		7,713
Total	$	10,192	$	9,554	$	9,274	$	10,052

Note 6. Long-Term Debt

On May 31, 2017, in connection with the Company’s acquisition of CorMatrix described in Note 7, Aziyo entered into a $12 million term loan facility (the “MidCap Loan Facility”) and an $8.0 million asset-backed revolving line of credit (the “MidCap Credit Facility”), under which the Company’s borrowing capacity was limited by certain qualifying assets, with a financial institution (the “May 2017 Financing”). The MidCap Loan Facility was amended in December 2017, February 2018 and July 2019 (all amendments being considered modifications) such that an additional $1.5 million, $3.0 million, and $3.5 million, respectively were received by the Company bringing the total aggregate principal amount outstanding under the MidCap Loan Facility to $20 million. The borrowings under the MidCap Loan Facility and the MidCap Credit Facility were fully repaid with a portion of the proceeds from the SWK Loan Facility (as defined below) as more fully described below.

Onn August 10, 2022 (the “Closing Date”), the Company entered into a senior secured term loan facility with SWK Funding LLC (“SWK”), as agent, and other lenders party thereto (the “SWK Loan Facility”) for an aggregate principal amount of $25 ~~million, with~~million. An initial draw of $21 million drawn was made on the Closing Date ~~(the “Initial Term Loan”) and~~with the additional $4 million ~~that becomes available, subject to~~drawn on December 14, 2022 upon satisfaction of the ~~achievement of specified operational and financial metrics by September 30, 2023 (the “Additional Term Loan”).~~amended terms enabling such receipt. The SWK Loan Facility also allows for the establishment of a separate, new asset-based revolving loan facility of up to $8 million, which had not been entered into as of ~~September~~June 30, ~~2022.~~2023. The SWK Loan Facility matures on August 10, 2027 and accrues interest, payable quarterly in arrears. Principal amortization of the SWK Loan Facility starts on November 15, 2024, which amortization may be extended to November 17, 2025 if certain conditions ~~to draw the Additional Term Loan~~ have been satisfied. Principal payments during the amortization period will be limited based on revenue-based caps. As of ~~September~~June 30, ~~2022,~~2023, quarterly principal payments are scheduled to begin on November 15, 2024, in an amount equal to 5% of the ~~Initial Term Loan~~outstanding principal on such principal payment commencement date with the balance paid at maturity. The SWK Loan Facility also includes both revenue and minimum liquidity covenants, restrictions as to payment of dividends, and is secured by all assets of the Company, subject to certain customary exceptions. On May 12, 2023, the Company entered into that certain First Amendment to the SWK Loan Facility Agreement with SWK, as agent, and the other lenders party thereto (the “Amendment”). The Amendment modified the minimum liquidity covenant applicable to the Company under the SWK Loan Facility Agreement, such that the Company must maintain a minimum liquidity of at least $5.0 million until August 15, 2023 (which date may be extended by SWK in its commercially-reasonable discretion, to November 15, 2023), and after such date, a minimum liquidity of at least the greater of (i) $5.0 million, and (ii) the sum of the operating cash burn (as defined in the SWK Loan Facility Agreement) for the two prior consecutive fiscal quarters then ended. As of ~~September~~June 30, ~~2022,~~2023, Aziyo was in compliance with its financial covenants under the agreement governing the SWK Loan Facility (the “SWK Loan Facility Agreement”).

~~Table of Contents~~

All of the SWK Loan Facility borrowings take the form of Secured Overnight Financing Rate (“SOFR”) loans and bear interest at a rate per annum equal to the sum of an applicable margin of (i) ~~8.75%~~7.75% and the “Term SOFR Rate” (based upon an interest period of 3 months), or (ii) if the Company has elected the PIK Interest option (as defined below), ~~4.75%~~3.75% and the “Term SOFR Rate.” The Company may elect a portion of the interest due, to be paid in-kind at a rate per annum of 4.5% (“PIK Interest”), and such election may be made (x) until November 15, 2024 if the conditions to draw the Additional Term Loan have not been met, or (y) if such conditions to draw the Additional Term Loan have been satisfied, until November 17, 2025. The “Term SOFR Rate” is subject to a floor of 2.75%. The agreement, as amended, governing

Table of Contents

the SWK Loan Facility also includes an exit fee equal to 6.5% of the aggregate principal amount funded prior to termination plus $62,500 and prepayment penalties equal to: (i) if such prepayment occurs prior to the first anniversary of the Closing Date, 2% of the aggregate principal amount funded prior to the termination plus remaining unpaid interest payments scheduled to be paid during the first year of the loan or (ii) if such prepayment occurs after the first anniversary of the Closing Date but prior to the second anniversary of the Closing Date, 2% of the aggregate principal amount funded prior to the termination. The weighted average interest rate on the SWK Loan Facility was ~~11.7%~~13.0% and 12.9% for the ~~period from August 10, 2022 through September~~three and six months ended June 30, ~~2022.~~2023, respectively.

On August 10, 2022, the Company issued to SWK Funding LLC a warrant (the “Warrant”) to purchase, in the aggregate, up to 187,969 shares of Class A common stock of the Company, $0.001 par value per share at an exercise price of $6.65 per share. The Warrant is immediately exercisable for up to ~~157,894~~187,969 shares of Class A common stock from time to time on or after the Closing Date. ~~Subject to and effective upon the borrowing of the Additional Term Loan, the Warrant will be exercisable for up to an additional 30,075 shares of Class A common stock.~~ The exercise price and number of shares of Class A common stock issuable upon exercise of the Warrant are subject to adjustment in the event of stock dividends, stock splits and certain other events affecting the Class A common stock. Unless earlier exercised or terminated in accordance with its terms, the Warrant will expire on the seventh anniversary of the Closing Date. Upon issuance, the Company valued the Warrant at approximately $0.6 million using the ~~Black Scholes~~Black-Scholes model. The recognition of the Warrant as well as deferred financing costs of approximately $0.5 million incurred in securing the SWK Loan Facility ~~served to reduce~~resulted in a reduction in the recorded value of the associated debt. The debt discount and deferred financing costs will be recognized as interest expense through the maturity of the loan.

The Company used $16 million of the proceeds of the SWK Loan Facility to repay all outstanding obligations on the MidCap Loan Facility and MidCap Credit Facility. Such payment included (i) $12.8 million to repay all outstanding principal and accrued interest on the MidCap Loan Facility, (ii) $1.7 million to pay the prepayment and exit fees on the MidCap Loan Facility and (iii) $1.5 million to repay the outstanding balance, accrued interest and exit fees on the MidCap Credit Facility. The prepayment fees, payment of unaccrued exit fees and the write-off of unamortized deferred financing costs resulted in a loss to the Company of approximately $1.2 million which has been recorded as other expense in the accompanying condensed consolidated statements of operations for the three and nine months ended September 30, 2022.

The SWK Loan Facility Agreement requires certain mandatory prepayments, subject to certain exceptions, with: (1) 100% of any net casualty proceeds in excess of $250,000 and (2) for non-ordinary course asset sales, an amount equal to the difference between (x) the proportion of divested gross profit (as defined in the SWK Loan Facility Agreement) to the Company’s total gross profit (as defined in the SWK Loan Facility Agreement) multiplied by the outstanding loans under the SWK Loan Facility and (y) the difference between $1,000,000 and the aggregate sale proceeds of any assets previously sold during the fiscal year. No such mandatory prepayments were required during the three and ~~nine~~six months ended ~~September~~June 30, ~~2022.~~2023.

In connection with the August 2022 debt refinancing, the Company used $16 million of the proceeds of the SWK Loan Facility to repay all outstanding obligations on its former MidCap term loan (“MidCap Loan Facility”) and former asset-backed revolving line of credit (“MidCap Credit Facility”). Borrowings under the MidCap Loan Facility ~~as amended,~~ bore interest at a rate per annum equal to the sum of (x) the greater of (i) 2.25% and (ii) the applicable London Interbank Offered Rate for U.S. dollar deposits divided by 1.00 minus the maximum effective reserve percentage for Eurocurrency funding (“LIBOR”) plus (y) 7.25%. The weighted average interest rate on MidCap Loan Facility was 9.5% ~~from January 1, 2022 through August 10, 2022 (the “Repayment Date”) and July 1,~~ ~~2022~~ ~~through the Repayment Date. The weighted average interest rate on the MidCap Loan Facility was 9.5%~~ for ~~both~~ the three and ~~nine~~six months ended ~~September~~June 30, ~~2021.~~

2022. Borrowings under the MidCap Credit Facility bore interest at a rate per annum equal to the sum of (x) the greater of (i) 2.25% and (ii) LIBOR plus (y) 4.95%. The weighted average interest rate on MidCap Credit Facility was 7.2% ~~from~~

~~Table of Contents~~

January 1, 2022 through the Repayment Date and July 1, 2022 through the Repayment Date. The weighted average interest rate on MidCap Credit Facility was 7.2% for both the three and nine months ended September 30, 2021.

During 2017, the Company restructured certain of its liabilities with a tissue supplier and entered into an unsecured promissory note totaling $2.1 million. The note bears interest at 5% and includes quarterly interest-only payments in 2017 and quarterly interest and principal payments from March 31, 2018 through August 31, 2021. The Company used $1.4 million of the proceeds from the SWK Loan Facility to repay the remaining balance on the promissory note; however the accrued interest on the promissory note was forgiven by the lender. ~~Such forgiveness resulted in a gain to the Company of approximately $0.4 million which has been recorded as other income in the accompanying condensed consolidated statements of operations~~ for the three and ~~nine~~six months ended ~~September~~June 30, 2022.

In May 2020, Aziyo entered into a promissory note with Silicon Valley Bank that provided for the receipt by the Company of loan proceeds totaling approximately $3.0 million (the “PPP Loan”) pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”). In September 2021, Aziyo was notified by the U.S. Small Business Administration that the entire balance of the Company’s PPP Loan and all related accrued interest was forgiven. Such forgiveness resulted in a gain to the Company of approximately $3.0 million which has been recorded as other income in the accompanying condensed consolidated statements of operations for the nine months ended September 30, 2021.

Long-term debt was comprised of the following (in thousands):


	September 30,		December 31,		June 30,		December 31,
	2022		2021		2023		2022
SWK/MidCap Loan Facility, net of unamortized discount and deferred financing costs	$	20,000	$	17,077
Note to Tissue Supplier		—		1,392
Total		20,000		18,469
Term Loan Facility, net of unamortized discount and deferred financing costs					$	24,927	$	24,260
Current Portion		—		(8,059)		—		—
Long-Term Debt	$	20,000	$	10,410	$	24,927	$	24,260

The fair value of all debt instruments, which is based on inputs considered to be Level 2 under the fair value hierarchy, approximates the respective carrying values as of ~~September~~June 30, ~~2022~~2023 and December 31, ~~2021.~~2022.

Note 7. Revenue Interest Obligation

On May 31, 2017, the Company completed an asset purchase agreement with CorMatrix Cardiovascular, Inc. ~~("CorMatrix"~~(“CorMatrix”) and acquired all CorMatrix commercial assets and related intellectual property (the ~~"CorMatrix Acquisition"~~“CorMatrix Acquisition”). As part of the CorMatrix Acquisition, the Company assumed a restructured, long-term obligation (the ~~“Revenue~~

Table of Contents

“Revenue Interest Obligation”) to Ligand Pharmaceuticals (“Ligand”) with an estimated present value on the acquisition date of $27.7 million. Subject to annual minimum payments of $2.75 million per year, the terms of the Revenue Interest Obligation require Aziyo to pay Ligand, 5% of future sales of the products Aziyo acquired from CorMatrix, including CanGaroo, ProxiCor, Tyke and VasCure, as well as products substantially similar to those products, such as the version of CanGaroo Aziyo is currently developing that is designed to include antibiotics.

Furthermore, a $5.0 million payment will be due to Ligand if cumulative sales of these products exceed $100 million and a second $5.0 million will be due if cumulative sales exceed $300 million during the ten-year term of the agreement which expires on May 31, 2027.

The Company recorded the present value of the estimated total future payments under the Revenue Interest Obligation as a long-term obligation, with the annual minimum payments, along with the expected payment timing of the first $5.0 million sales milestone payment noted above, serving to establish the short-term portion. At each reporting period, the value of the Revenue Interest Obligation is re-measured based on current estimates of future payments, with changes to be recorded in the condensed consolidated statements of operations using the catch-up method. There was no change to estimated future payments during the three and ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 and ~~2021,~~2022, and thus, no re-measurement gain or loss was recognized. Interest expense related to the Revenue Interest Obligation of approximately

~~Table of Contents~~

~~$0.7~~ $0.5 million and $0.7 million was recorded for ~~both~~ the three months ended ~~September~~June 30, 2023 and 2022, ~~and 2021~~respectively and approximately ~~$2.0~~$1.1 million and $1.3 million was recorded for ~~both~~ the ~~nine~~six months ended ~~September~~June 30, 2023 and 2022, ~~and 2021.~~respectively.

Note 8. Commitments and Contingencies

~~Operating Leases~~

The Company leases two production facilities and one administrative and research facility under non-cancelable operating lease arrangements that expire through November 2025. Each of these leases contain renewal options and escalation clauses based upon increases in the lessors’ operating expenses and other charges. The Company also has a short-term lease for a small administrative-only facility.

The Company records rent expense on a straight-line basis over the life of the lease and the difference between the average rent expense and cash payments for rent is recorded as deferred rent and is included in other current and long-term liabilities on the balance sheet. Rent expense was approximately $0.3 million for both the three months ended September 30, 2022 and 2021, and was approximately $0.9 million for both the nine months ended September 30, 2022 and 2021, and is included as a component of either cost of goods sold or general and administrative expenses.

Cook Biotech License and Supply Agreements

Aziyo has entered into a license agreement with Cook Biotech (“Cook”) for an exclusive, worldwide license to the porcine tissue for use in the Company’s Cardiac Patch and CanGaroo products, subject to certain co-exclusive rights retained by Cook (the “Cook License Agreement”). The term of such license is through the date of the last to expire of the licensed Cook patents, which is anticipated to be July 2031. Along with this license agreement, Aziyo entered into a supply agreement whereby Cook would be the exclusive supplier to Aziyo of the licensed porcine tissue. Under certain limited circumstances, Aziyo has the right to manufacture the licensed product and pay Cook a royalty of 3% of sales of the Aziyo-manufactured tissue. The supply agreement expires on the same date as the related license agreement. No royalties were paid to Cook during the three and ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 or ~~2021.~~2022. Aziyo has also entered into an amendment to the Cook License Agreement (the “Cook Amendment”) in order to add fields of exclusive use. Specifically, the Cook Amendment provides for a worldwide exclusive license to the porcine tissue for use with neuromodulation devices in addition to cardiovascular devices. The Cook Amendment includes license fee payments of $0.1 million per year in each of the years 2021 through 2026. Such license payments would accelerate if a change in control, as defined in the Cook Amendment, occurs within Aziyo. The Company, in its sole discretion, can terminate the Cook License Agreement at any time.

Legal Proceedings

From time to time, the Company may be involved in claims and proceedings arising in the course of the Company’s business. The outcome of any such claims or proceedings, regardless of the merits, is inherently uncertain. The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available.

Table of Contents

FiberCel Litigation

In June 2021, the Company announced a voluntary recall of a single lot of FiberCel fiber viable bone matrix. Since September 2021, 5576 lawsuits (78 plaintiffs) in Indiana, Delaware, Florida, Maryland, Colorado, Michigan, Ohio, Kentucky, Oregon, North Carolina, Louisiana, Illinois, Virginia, California, Pennsylvania, and ~~Louisiana~~Arizona have been filed against Aziyo Biologics Inc., certain Medtronic entities, and others alleging that the plaintiffs were exposed to and/or contracted tuberculosis and/or suffered substantial symptoms and complications following the implantation of FiberCel during spinal fusion operations. Such lawsuits were filed in Indiana state court (collectively, the “Indiana State Complaints”); the Superior Court of the State of Delaware (collectively, the “Delaware State Complaints”); the Circuit Court of Maryland (collectively, the “Maryland State Complaints”); the Court of Common Pleas of Ohio ~~(“Ohio State Complaint”);~~and the ~~Northern~~U.S. District Court of the Southern District of Ohio ~~(“Ohio Federal Complaint”~~(collectively, the “Ohio Complaints”); the U.S. District Court for the Western District of North Carolina (“North Carolina Federal Complaint”); the U.S. District Court

~~Table of Contents~~

for the Northern District of Florida (“and the U.S. District Court for the Southern District of Florida (collectively, the “Florida Federal ~~Complaint”~~Complaints”); the U.S. District Court for the Eastern District of Michigan ~~and the Eastern District of~~(collectively “the Michigan ~~(collectively “Michigan~~ Federal Complaints.”); the U.S. District Court for the District of Colorado (“Colorado Federal Complaint”); the U.S. District Court for the District of Oregon (“Oregon Federal Complaint”); the Fayette, Kentucky Circuit Court and the U.S. District Court for the Eastern District of Kentucky (collectively, the “Kentucky Complaints.”); the U.S. District Court for the Western District of Louisiana (“Louisiana Federal Complaint”).; the Illinois Circuit Court (collectively, the “Illinois State Complaints”); the U.S. District Court for the Eastern District of Virginia (“Virginia Federal Complaint”); the U.S. District Court for the Eastern District of Pennsylvania (“Pennsylvania Federal Complaint”); Philadelphia County Court of Common Pleas (“Pennsylvania State Complaint”); the U.S. District Court for the Central District of California (“California Federal Complaint”) and the U.S. District Court for the District of Arizona (“Arizona Federal Complaint.”)

Plaintiffs in the Indiana State Complaints allege a cause of action under Indiana’s Product Liability Act, citing manufacturing defects, defective design and failure to properly warn and instruct, and several of the complaints allege loss of consortium. Plaintiffs in these actions assert that the defendants are strictly liable or have breached the duty of care owed to plaintiffs by failing to exercise reasonable care in designing, manufacturing, marketing and labeling FiberCel and are seeking various types of damages, including economic damages, non-economic damages and loss of consortium. Plaintiffs in one of the Indiana State Complaints allege causes of action for product liability, negligence, breach of express and implied warranties, and punitive damages. Each of the plaintiffs in the Delaware State Complaints alleges negligence, breach of implied warranty, breach of express warranty, and medical monitoring and punitive damages, and two also allege loss of consortium. Plaintiffs in the Delaware State Complaints are seeking economic, consequential, and punitive damages. The Maryland State Complaints assert claims of negligence, breach of implied warranty, breach of express warranty, medical monitoring, and loss of consortium. The Florida Federal Complaint contains three strict liability claims for defective design, defective manufacture, and failure to warn. A claim for punitive damages is also pled. The Ohio State Complaint alleges causes of action for product liability and negligence and seeks compensatory damages. The Colorado Federal Complaint asserts causes of action for strict product liability, misrepresentation, negligence, breach of express warranty, and breach of implied warranty of merchantability. The Michigan Federal Complaints assert causes of action for negligence, gross negligence breach of implied warranty, breach of express warranty, intentional infliction of emotional distress, and liability under the res ipsa loquitur doctrine. The Michigan Federal Complaints seek compensatory damages and punitive damages. The North Carolina Federal Complaint alleges causes of action for negligence, defective design, breach of implied warranty, breach of express warranty, and loss of consortium, and seeks both compensatory and punitive damages. The Oregon Federal Complaint asserts strict liability claims for defective design, defective manufacture, and failure to warn, and seeks compensatory damages. The Ohio Federal Complaint asserts strict liability claims for defective manufacturing, inadequate warning, nonconformance with representations, and also alleges loss of consortium and seeks compensatory damages. The Kentucky Complaints assert strict liability claims based on manufacturing defect, design defect, failure to warn, negligence, breach of implied warranty, breach of express warranty, and seek recovery for medical monitoring, loss of consortium, compensatory damages, and punitive damages. The Louisiana Federal Complaint asserts claims of violation of the Louisiana products liability act, negligence and gross negligence, breach of implied warranty, breach of express warranty and seek recovery for medical monitoring. The Illinois State Complaints contain claims of strict liability- defective design and manufacturing, breach of express warranty, breach of implied warranty and negligence and seek compensatory damages. The Virginia State Complaint asserts causes of action for negligent failure to warn, negligence, breach of implied warranty, breach of express warranty and seeks recovery for medical monitoring, compensatory damages and punitive damages. The California Federal Complaint advances claims of strict liability

Table of Contents

(defective design and manufacture), negligence and breach of implied warranty and seeks compensatory damages and recovery for medical monitoring. The Arizona Federal Complaint asserts strict product liability claims for defective design, manufacture and failure to warn, negligence, breach of implied warranty and breach of express warranty and seeks recovery for medical monitoring, loss of consortium, compensatory damages, and punitive damages. Plaintiff in the Pennsylvania State Complaint asserts claims for strict liability, negligence, breach of implied warranty, and breach of express warranty, as well as claims under the Wrongful Death Act and the Survival Act and seeks compensatory and punitive damages.

In addition to the above, there ~~have been 42~~are 31 claims related to the FiberCel recall that have not yet resulted in a lawsuit. The Company refers to all of the aforementioned litigation, or claim notices, collectively as the “FiberCel Litigation.”

~~In October~~Since August 2022, the Company has engaged in a process to negotiate and attempt to resolve many of the cases in the FiberCel Litigation. ~~The Company also mediated and resolved a Maryland lawsuit in August 2022.~~ In total, Aziyo’s liability in 2427 of the cases was settled ~~(23 of which are pending finalization of the related settlement agreements)~~ for a total of approximately ~~$7.2~~$7.5 million. The settled matters included cases from the Indiana State Complaints, Ohio State Complaint, Florida Federal Complaint, Colorado Federal Complaint, Delaware State Complaints and Maryland Complaint, along with claims in six states. Of these settled matters, ~~one case was~~26 cases were both settled and paid as of ~~September~~June 30, ~~2022~~2023 for a total cash outlay of ~~$1.3~~$7.3 million. For the remaining 7382 cases for which settlements have not been reached, the Company estimated a probable loss related to each case and has recorded a liability at an estimated amount of ~~$11.7~~$14.3 million bringing the total estimated liability at ~~September~~June 30, ~~2022~~2023 to ~~$17.6~~$14.5 million, which is recorded as Contingent Liability for FiberCel Litigation in the accompanying ~~condensed~~ consolidated balance sheets. Although ~~we believe~~the Company believes there is a possibility that a loss in excess of the amount recognized exists, ~~we are~~the Company is unable to estimate the possible loss or range of loss in excess of the amount recognized at this time. In order to reasonably estimate the liability for the unsettled FiberCel Litigation cases, the Company, along with outside legal counsel, has assessed a variety of factors, including (i) the extent of the injuries incurred, (ii) recent experience on the settled claims, (iii) settlement offers made to the other parties to the litigation and (iv) any other factors that may have a material effect on the FiberCel Litigation. While the Company believes its estimated liability to be reasonable, the actual

~~Table of Contents~~

loss amounts are highly variable and turn on a case-by-case analysis of the relevant facts. As more information is learned about asserted claims and potential future trends, adjustments may be made to this Contingent Liability for FiberCel Litigation as appropriate.

Defense costs are recognized in the accompanying ~~condensed~~ consolidated statements of operations as incurred.

The Company has purchased insurance coverage that, subject to common contract exclusions, provided coverage for the FiberCel Litigation product liability losses as well as legal defense costs. Additionally, the Company has various potential indemnity and/or contribution rights against third party sources with respect to certain product liability losses. When settlements are reached and/or amounts are recorded in the related Contingent Liability for FiberCel Litigation, the Company calculates amounts due to be reimbursed pursuant to the terms of the coverage and related agreements, and pursuant to other indemnity or contribution claims, in respect of product liability losses and related defense costs. The amounts probable of reimbursement or recovery from this calculation are recorded as receivables. The determination that the recorded receivables are probable of collection is based on the terms of agreements reached in respect of indemnity and contribution claims as well as the advice of the Company’s outside legal counsel. These receivables at ~~September~~June 30, ~~2022~~2023 totaled ~~$17.2~~$8.9 million and are recorded as Receivables of FiberCel Litigation Costs in the accompanying ~~condensed~~ consolidated balance sheets.

The indemnity and contribution receivables amount at ~~September~~June 30, ~~2022~~2023 represents amounts that are not believed to be subject to any current dispute. At ~~September~~June 30, ~~2022,~~2023, the Company continues to pursue up to $3.8 million or more in additional amounts in respect of such indemnity and contribution claims and as such, has not been reflected as part of this receivable. The Company will vigorously pursue its position with respect to this ~~amount~~amount.

Viable Bone Matrix Recall

In July 2023, the Company announced a voluntary recall of a single lot of a certain viable bone matrix (“VBM”) product and ~~while~~the market withdrawal of all of its VBM products produced after a specified date (the “VBM Matter”). Such VBM products are within the Company’s Orthobiologics business. Notice of the voluntary recall was issued to centers after the Company learned of post-surgical Mycobacterium tuberculosis (MTB) infections in two patients treated with a VBM product from a single donor lot. Prior to release, samples from this specific lot had tested negative for MTB by an independent laboratory using a nucleic acid test that is designed to specifically detect the MTB organism.

Table of Contents

The VBM recall and market withdrawal necessitated the establishment of a product returns reserve and reversal of revenue totaling $3.0 million, which is included in accrued expenses and other current liabilities in the condensed consolidated balance sheet as of June 30, 2023. Furthermore, the Company has written off the full value of its VBM inventory on-hand at June 30, 2023 resulting in a $2.0 million charge to cost of goods sold in the condensed consolidated income statement for the three and six months ended June 30, 2023. Such writedown was deemed necessary due to the limited shelf-life of the inventory and the inability to sell the VBM inventory until a valid MTB test can be identified or developed, both of which are uncertain at this time.

At present, no lawsuits have been filed or claims asserted as a result of the VBM Matter. Management has determined that there is a reasonably possible likelihood of material claims due to the recall and market withdrawal but does ~~expect~~not believe that the claims are probable or estimable. Consequently, management has determined that no liability for such possible claims would be recognized for the VBM recall and market withdrawal as of June 30, 2023. While unknown at this time, possible losses in connection with the VBM Matter could have a material effect on the Company’s financial position and results of operations. Consistent with the FiberCel Litigation above, the Company has purchased insurance coverage that, subject to ~~be successful in recovering at least an additional $3.8 million or more.~~ common contract exclusions, provide coverage for the possible claims associated with the VBM Matter as well as legal defense costs.

As of both ~~September~~June 30, ~~2022~~2023 and ~~December 31, 2021,~~2022, the Company was not a party to, or aware of, any ~~material~~ legal matters or claims with material financial exposure, except for the FiberCel Litigation.

Note 9. Net Loss Per Share Attributable to Common Stockholders


	Three Months Ended				Nine Months Ended				Three Months Ended				Six Months Ended
(in thousands, except share and per share data)	September 30,				September 30,				June 30,				June 30,
	2022		2021		2022		2021		2023		2022		2023		2022
Numerator:
Net loss attributable to common stockholders	$	(9,910)	$	(8,316)	$	(27,457)	$	(15,768)
Net loss									$	(10,621)	$	(9,398)	$	(18,595)	$	(17,547)
Denominator:
Weighted average number of common shares, basic and diluted		13,660,555		10,235,350		13,618,580		10,229,974
Net loss per common share attributable to common stockholders, basic and diluted	$	(0.73)	$	(0.81)	$	(2.02)	$	(1.54)
Weighted average number of common shares - basic and diluted										16,223,919		13,620,196		16,208,905		13,597,243
Net loss per share - basic and diluted									$	(0.65)	$	(0.69)	$	(1.15)	$	(1.29)

The Company’s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders:


	September 30,		June 30,
	2022	2021	2023	2022
Options to purchase common stock	1,755,447	1,390,234	1,666,549	2,370,226
Restricted stock units	373,332	235,885	303,935	773,285
Class A common stock warrants			187,969	—
Total	2,128,779	1,626,119	2,158,453	3,143,511

Note10. Segment Information

The Company operates in four segments. These segments are based on financial information that is utilized by the Company’s CODM to assess performance and allocate resources. The Company determined its operating and reportable segments to be consistent with its major product groupings – Device Protection, Women’s Health, Orthobiologics and Cardiovascular.

2322

Table of Contents

~~Note 10. Related Party Transactions~~

As part of the contribution of assets transacted from Tissue Banks International, now KeraLink International (“KeraLink”), to Aziyo upon formation of the Company, a provision existed which guaranteed a certain level of working capital, as defined, on the opening balance sheet of Aziyo. Such guarantee was largely finalized in 2016; however, an additional $0.4 million was received by the Company in connection with a settlement reached in 2018. Furthermore, as part of the 2018 settlement, it was agreed that when KeraLink sells its Aziyo common shares for net proceeds greater than $550,000, KeraLink is obligated to pay Aziyo $550,000 within three days of such cash being received. In May 2021, KeraLink sold Aziyo common shares for proceeds in excess of $550,000, and as such, remitted $550,000 to Aziyo in full satisfaction of the 2018 settlement. Amounts received in connection with this settlement were recorded as other income in the accompanying condensed consolidated statements of operations for the nine months ended September 30, 2021.

~~Note11. Segment Information~~

The Company operates as one segment, regenerative medicines. The segment is based on financial information that is utilized by the Company’s Chief Operating Decision Maker (“CODM”), who is the Company’s Chief Executive Officer, to assess performance and allocate resources.

~~For the three and nine months ended September 30, 2022 and 2021, the~~ Company’s net sales disaggregated by ~~the major sources - Core Products and Non-Core Products (see Note 1) -~~segment were as follows (in thousands):


	Three Months Ended				Nine Months Ended				Three Months Ended				Six Months Ended
	September 30,				September 30,				June 30,				June 30,
	2022		2021		2022		2021		2023		2022		2023		2022
Sales by product
Core Products	$	8,949	$	8,588	$	26,141	$	29,230
Non-Core Products		3,440		2,897		10,381		7,299
Net sales:
Device protection									$	2,221		2,244	$	4,571	$	4,296
Women's health										2,400		1,824		4,695		3,458
Orthobiologics										3,945		6,476		10,603		12,720
Cardiovascular										1,730		2,094		3,477		3,659
Total Net Sales	$	12,389	$	11,485	$	36,522	$	36,529	$	10,296	$	12,638	$	23,346	$	24,133

The Company’s gross profit disaggregated by segment were as follows (in thousands):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2023		2022		2023		2022
Gross profit:
Device protection	$	1,498	$	1,430	$	3,294	$	2,749
Women's health		907		1,004		1,959		1,678
Orthobiologics		(1,733)		1,642		1,225		3,545
Cardiovascular		1,157		1,671		2,532		2,906
Gross profit, excluding intangible asset amortization	$	1,829		5,747		9,010		10,878
Intangible asset amortization expense		849		849		1,699		1,699
Gross profit	$	980	$	4,898	$	7,311	$	9,179

The following table is a reconciliation of segment gross profit to the consolidated loss before provision for income taxes (in thousands):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2023		2022		2023		2022
Gross profit, excluding intangible asset amortization	$	1,829	$	5,747	$	9,010	$	10,878

Adjustments:
Intangible asset amortization expense		(849)		(849)		(1,699)		(1,699)
Sales and marketing		(3,618)		(5,406)		(8,974)		(10,224)
General and administrative		(4,005)		(4,711)		(7,684)		(8,736)
Research and development		(1,171)		(2,617)		(2,974)		(4,889)
FiberCel litigation costs		(1,271)		(346)		(3,182)		(434)
Loss from operations		(9,085)		(8,182)		(15,503)		(15,104)
Interest expense		1,524		1204		3,068		2,419
Loss before provision for income taxes	$	(10,609)	$	(9,386)	$	(18,571)	$	(17,523)

2423

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes included elsewhere in this Quarterly Report, as well as the audited financial statements and the related notes thereto, and the discussion under Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report. This discussion contains forward-looking statements reflecting our current expectations, estimates, plans and assumptions concerning events and financial trends that involve risks and may affect our future operating results and financial position. Actual results and the timing of events may differ materially from those contained in these forward-looking statements due to a number of factors, including those discussed in the sections entitled “Forward-Looking Statements” and Part II, Item 1A. “Risk Factors” of this Quarterly Report and in the section entitled “Risk Factor Summary” and in Part I, Item IA. “Risk Factors” of our Annual Report.

Overview

We are a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing ~~surgery, concentrating on~~surgery. We seek to leverage our unique understanding of biologics to improve the interaction between medical devices and patients, ~~receiving implantable medical devices.~~with the goal of reducing complications and improving healing. From our proprietary tissue processing platforms, we have developed a portfolio of advanced regenerative medical products that are designed to ~~be very similar to~~mimic the healing response of natural biological material. Our proprietary products ~~which we refer to as our Core Products,~~ are designed to address the ~~implantable electronic device/cardiovascular, orthopedic/spinal repair~~device protection, women’s health, orthobiologics and ~~soft tissue reconstruction~~cardiovascular markets, which represented a combined $3 billion market opportunity in the United States in ~~2020.~~2019. To expand our commercial reach, we have commercial relationships with major medical device companies, such as Boston Scientific, Biotronik, Sientra and ~~Biotronik,~~LeMaitre Vascular, to promote and sell some of our ~~Core Products.~~products. We believe our focus on our unique regenerative medicine platforms ~~and our Core Products~~ will ultimately maximize our probability of continued clinical and commercial success and will create a long-term competitive advantage for us.

We estimate that, over the past two years, approximately two million patients per year in the United States ~~are~~were implanted with either medical devices, such as pacemakers, defibrillators, neuro-stimulators, spinal fusion and trauma fracture hardware or tissue expanders for breast reconstruction. This number ishas been driven by advances in medical device technologies, reimbursement models focused on patient outcomes, and an aging population with a growing incidence of comorbidities, including diabetes, obesity and cardiovascular and peripheral vascular diseases. These comorbidities can exacerbate various immune responses and contribute to other complications ~~that can be triggered by a~~upon device implant.

Our ~~Core Products~~products are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as infection, scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection. We ~~believe that~~have leading products in each of our four priority markets: device protection, cardiovascular, orthobiologics and women’s health. In device protection, we ~~have developed~~sell the only ~~biomaterial~~biological envelope, ~~which is covered~~protected by a ~~number of patents~~global patent portfolio, that forms a natural, systemically vascularized pocket for holding implanted electronic devices. WeIn cardiovascular, we sell our SIS ECM for use as an intracardiac and vascular patch. In orthobiologics, we have a proprietary processing technology for manufacturing a comprehensive portfolio of bone regenerative products ~~for use in orthopedic/spinal repair that preserves a cell’s~~designed to promote the body’s ability to regenerate healthy bone, ~~and decelerates~~osteogenesis, while decreasing cell apoptosis, or programmed cell death. WeIn women’s health, we have a patented cell removal technology that produces undamaged extracellular dermal matrices ~~for use~~with superior handling, designed to promote faster healing and reduce inflammation. In pre-clinical and clinical studies, our products have supported and, in ~~soft~~some cases, accelerated tissue ~~reconstruction.~~

Our Non-Core Products are those fulfilled through tissue processing contracts at our Richmond, California facility. These contracts serve to utilize as much as possible of the starting human biological material from which we produce our orthopedic/spinal repairhealing, and soft tissue reconstruction products, leverage our existing overhead and improve our cash flow. The resulting processed materials, including particulate bone, precision milled bone, cellular bone matrix, acellular dermis and other soft tissue products, are sold to medical/surgical companies as finished products and as a subcomponent of their products. Additionally, we process amniotic membrane as finished product for selected customers.thereby improved patient outcomes.

We process all of our products at our two manufacturing facilities in Roswell, Georgia and Richmond, California, and stock inventory of raw materials, ~~components~~supplies and finished goods at those locations. We rely on a single or limited number of suppliers for certain raw materials and ~~components.~~supplies. Except for the porcine tissue supplier of our raw materials for our CanGaroo and cardiovascular products, which is Cook Biotech, we generally have no long-term supply agreements with our suppliers, as we obtain supplies on a purchase order basis. Specifically, we acquire donated human tissue directly through tissue procurement firms engaged by us. Our products are shipped either directly to hospital customers or through distribution partners.

2524

Table of Contents

~~through tissue procurement firms engaged by us. We primarily ship our Core Products from our facilities directly to hospital customers.~~

Since inception, we have financed our operations primarily through private placements of our convertible preferred stock, amounts borrowed under our credit facilities, sales of our products and, more recently, with proceeds from our initial public offering (“IPO”) and a private placement of our common stock. We have devoted the majority of our resources to acquisitions and integration, manufacturing and administrative costs, general and administrative, research and development, clinical activity, purchase of property and equipment used in the production activities of our Richmond, California facility and investing in our commercial infrastructure through our direct sales force and our commercial partners in order to expand our presence and to promote awareness and adoption of our products. As of ~~September~~June 30, ~~2022,~~2023, we had ~~166 employees, of which 26 were direct sales representatives.~~151 employees.

~~For the nine months ended September 30, 2022, we~~We have incurred significant operating losses since our inception. We incurred a net loss of ~~$27.5~~$18.6 million ~~and~~for the six months ended June 30, 2023. Our accumulated deficit as of ~~September~~June 30, ~~2022, we had an accumulated deficit of $132.5~~2023 was $156.6 million. ~~In addition, during the nine months ended September 30, 2022, we used $16.2 million and $5.7 million of cash in operating and financing activities, respectively.~~ We expect our losses to continue ~~to incur significant expenses and operating losses~~ for the foreseeable future ~~as we expand~~and these losses will continue to have an adverse effect on our ~~product development and clinical and research activities and to the extent we grow our sales organization to coincide with product launches.~~financial position. Because of the numerous risks and uncertainties associated with our commercialization and development efforts, including risks relating to our ability to obtain FDA clearance for the next generation of our flagship CanGaroo product, CanGaroo RM, and our ability to successfully commercialize this product, we are unable to predict when we will become profitable, and we may never become profitable. Our inability to achieve and then maintain profitability would negatively affect our business, financial condition, results of operations and cash flows.

Our ability to achieve profitability will depend on our ability to generate sales from existing or new products sufficient to exceed our ongoing operating expenses and capital requirements. Because of the numerous risks and uncertainties affecting product sales and our ongoing commercialization and product development efforts, we are unable to predict with any certainty whether we will be able to increase sales of our products or the timing or amount of ongoing expenditures we will be required to incur. Accordingly, even if we are able to increase sales of our products, we may not become profitable.

In order to mitigate the current and potential future liquidity issues caused by the matters noted above, we may seek to raise capital through the issuance of common stock, restructure our Revenue Interest Obligation, or pursue asset sale or ~~licensing~~other transactions. However, such transactions may not be successful and we may not be able to raise additional equity, refinance ~~or restructure~~ our debt instruments, or sell assets on acceptable terms, or at all. As such, based on our current operating plans, we believe there is uncertainty as to whether our future cash flows along with our existing cash, ~~potential~~ availability under ~~our~~the SWK Loan Facility (described below under ~~“– Liquidity and Capital Resources –~~ “—Credit Facilities”), issuances of additional equity and cash generated from expected future sales will be sufficient to meet our anticipated operating needs through twelve months from the financial statement issuance date. Due to these factors, there is substantial doubt about our ability to continue as a going concern within one year after the issuance of the financial statements.

Viable Bone Matrix Recall and FiberCel Recall

~~Impact~~Viable Bone Matrix Recall

In July 2023, we announced a voluntary recall of ~~COVID-19~~a single lot of a certain viable bone matrix product and the market withdrawal of all of our viable bone matrix (“VBM”) products produced after a specified date. Notice of the voluntary recall was issued to centers after we learned of post-surgical Mycobacterium tuberculosis (MTB) infections in two patients treated with a VBM product from a single donor lot. Prior to release, samples from this specific lot had tested negative for MTB by an independent laboratory using a nucleic acid test that is designed to specifically detect the MTB organism.

Since issuing the recall, we have been working with the U.S. Food and Drug Administration (“FDA”) and the U.S. Centers for Disease Control and Prevention (“CDC”) to identify and secure all unused product, ascertain the medical status of patients treated with the recalled product, understand whether there is any relationship between the post-surgical infections and the recalled product lot and determine the medical cause of these infections. We have identified the 115 units comprising the single product lot in question. Based on information from the CDC, 49 units within this product lot were implanted into 36 patients and the remaining units were either never distributed by us or were returned to either us or the CDC. Of these 36 patients, CDC has identified at least five patients who have exhibited clinical or diagnostic findings consistent with tuberculosis infection.

We ~~continue~~are continuing to work closely ~~monitor~~with the ~~impact of~~FDA and CDC in investigating the ~~COVID-19 pandemic and its variants on our business. In March 2020,~~circumstances surrounding the World Health Organization declared COVID-19 a global pandemic and recommended various containment and mitigation measures worldwide. Since that time, the number of procedures performed using our products has intermittently decreased, as governmental authorities in the United States have recommended, and in certain cases required, that elective, specialty and other non-emergency procedures and appointments be suspended or canceled in order to avoid patient exposure to medical environments and the risk of potential infection with COVID-19, and to focus limited resources and personnel capacity on the treatment of COVID-19 patients. As a result, beginning in March 2020, a significant number of procedures using our products have intermittently been postponed or cancelled, which has negatively impacted sales of our products. These measures and challenges will likely continue for the duration of the pandemic, which is uncertain, and may reduce our net sales in the future and negatively impact our business, financial condition and results of operations while the pandemic continues.event.

2625

Table of Contents

In addition, numerous state and local jurisdictions, including those where our facilities are located, imposed, and others in the future may impose or re-impose, “shelter-in-place” orders, quarantines, executive orders and similar government orders and restrictions for their residents to control the spread of COVID-19. Such orders or restrictions resulted in reduced operations at our manufacturing facilities and service providers, travel restrictions and cancellation of events, and have restricted the ability of our sales representatives and those of our commercial partners and independent sales agents to attend procedures in which our products are used, among other effects, thereby negatively impacting our operations.

While access to procedures for our sales representatives and independent sales agents have improved, the extent to which the COVID-19 pandemic impacts our future financial condition and results of operations will depend on future events and developments, which are highly uncertain and cannot be predicted, including the severity and spread of the disease and the effectiveness of actions to contain the disease or treat its impact, among others. As new information regarding COVID-19 continues to emerge, and, as variants of COVID-19 emerge, it is difficult to predict the degree to which this disease will ultimately affect our business.

FiberCel Recall

In June 2021, we issued a voluntary recall pertaining to a single donor lot of our FiberCel, aour bone repair product formerly distributed by Medtronic, after learning of postsurgical infections reported in several patients treated with the product, including some patients that tested positive for tuberculosis. For information about the FiberCel Litigation in which we are involved, the impact of such proceedings on our financial statements included in this Quarterly Report, and the possible future financial implications, see Note 8 to the condensed consolidated financial statements included elsewhere in this Quarterly Report. The impact of FiberCel Litigation on our results of operations for the periods covered by this Quarterly Report are discussed below under “ – Results of Operations.”

Recent Strategic Transactions

We operate four distinct business units – Device Protection, Cardiovascular, Women’s Health, and Orthobiologics. We have received interest and are actively considering material strategic transactions in each of these business units. The types of transactions under consideration include exclusive supply agreements, co-promotion arrangements, exclusive distribution partnerships, and whole business unit divestitures. The most advanced of these potential transactions are based on written statements of interest with detailed terms that include cash offers for acquisition of the unit, and partnership opportunities with significant upfront payments and purchase commitments.

~~Each business unit has at least one contemplated transaction~~In March 2023, we entered into an agreement with Sientra, a medical aesthetics company uniquely focused on plastic surgery, to expand the ~~potential, we believe, to be consummated, add non-dilutive capital, and enhance shareholder value. However, we intend to be selective and only execute agreements that we believe are~~distribution of our women’s health segment product line, SimpliDerm. Under the agreement terms, Aziyo will grant Sientra certain non-exclusive rights in the ~~best long-term interest~~United States to market, sell and distribute SimpliDerm for select use in reconstruction surgery.

In April 2023, we entered into an agreement with LeMaitre Vascular, a provider of ~~shareholders. As a result, it is possible that we do not execute any~~vascular devices, implants and services, granting LeMaitre Vascular the exclusive U.S. distribution rights for the products within its cardiovascular segment: ProxiCor® PC, ProxiCor® CTR, Tyke® and VasCure®. The term of the ~~aforementioned. Moreover, if we do execute one~~collaboration is three years, and LeMaitre Vascular will have the exclusive option to acquire the product line following the first year or ~~more of these transactions, there can be no assurance that the terms of any such transaction would be favorably received by the market.~~ under certain other circumstances.

CanGaroo RM Status

~~A 510(k) submission for pre-market clearance~~We are currently developing a version of the CanGaroo Envelope, CanGaroo RM, ~~Antibacterial Envelope,~~that combines the ~~only biomaterial~~ envelope with antibiotics and is designed to ~~mitigate complications in implantable~~reduce the risk of infection following surgical implantation of an electronic ~~device procedures, is currently under review by the U.S. FDA. We recently held a positive meeting with~~device. Based on feedback from the FDA, ~~that clarified certain information requirements related~~CanGaroo RM will require clearance of a 510(k) submission to ~~our~~be marketed in the United States. We submitted the required 510(k) ~~submission.~~in April 2022 and, in March 2023, received a Not Substantially Equivalent (“NSE”) letter from FDA requiring us to address questions relating to drug testing, primarily a request by FDA to modify an in vitro drug release assay employed as a manufacturing control. We ~~will be~~intend to address the questions raised in the NSE letter and continue to work with FDA for potential clearance via the 510(k) pathway. We anticipate being able to complete our responses to outstanding questions from FDA in ~~time for an anticipated CanGaroo RM marketing clearance in~~ the ~~first quarter of 2023.~~

2023 calendar year.

Impact of Inflation

Inflationary factors, such as increases in our cost of goods sold or other operating expenses, may adversely affect our operating results. While it is difficult to accurately measure the impact of inflation due to the imprecise nature of the estimates required, we do not believe inflation had a material effect on our financial condition or results of operations during the ~~nine~~three or six months ended ~~September~~June 30, ~~2022~~2023 and ~~2021.~~2022. We cannot assure you, however, that we will be able to

~~Table of Contents~~

increase the selling prices of our products or reduce our operating expenses in an amount sufficient to offset the effects future inflationary pressures may have on our gross margin. Accordingly, we cannot assure you that our financial condition and results of operations will not be materially impacted by inflation in the future.

Components of Our Results of Operations

Net Sales

We recognize revenue on the sale of our ~~Core Products~~products. During the three months ended June 30, 2023, our device protection and ~~our Non-Core Products. With respect to our Core Products, CanGaroo and our~~ cardiovascular products ~~are~~were sold to hospitals and other healthcare facilities primarily through our direct sales force, commercial partners or independent sales ~~agents. Our orthopedic/spinal repair~~agents; however, beginning in April 2023, our cardiovascular products ~~are~~have been sold domestically through our distribution agreement with LeMaitre Vascular and internationally through commercial partners. Our ~~soft tissue reconstruction~~women’s health product, SimpliDerm, is sold directly to hospitals and other healthcare facilities through independent sales ~~agents.~~agents or through our distribution agreement with Sientra. Our orthobiologics products

Table of Contents

are sold through commercial partners. Our contract manufacturing products are sold directly to corporate customers. Gross to net sales adjustments include sales returns and prompt payment and volume discounts.

Expenses

In recent years, we have incurred significant costs in the operation of our business. We expect that our recurring operating costs will largely stabilize, or increase at modest rates, in the near future through the identification of efficiencies as we grow. We may, however, still experience more significant expense increases as we expand our product development and clinical and research ~~activities and to the extent we grow our sales organization to coincide with product launches.~~activities. As a result, we will need to generate significant net sales in order to achieve profitability. Below is a breakdown of our main expense categories and the related expenses incurred in each category:

Cost of Goods Sold

Our cost of goods sold relate to purchased raw materials and the processing and conversion costs of such raw materials consisting primarily of salaries and benefits, supplies, quality control testing and the manufacturing overhead incurred at our processing facilities in Richmond, California and Roswell, Georgia. Both facilities have additional capacity, which if utilized, would further leverage our fixed overhead. Cost of goods sold also includes the amortization of intangibles generated from the CorMatrix Acquisition in 2017.

Sales and Marketing Expenses

Sales and marketing expenses are primarily related to our direct sales force, consisting of salaries, commission compensation, fringe benefits, meals and other expenses. Auto and travel costs have also historically contributed to sales and marketing ~~expenses, albeit to a lesser extent due to the COVID-19 pandemic.~~expenses. Outside of our direct sales force, we incur significant expenses relating to commissions to our CanGaroo commercial partners and independent sales agents. Additionally, this expense category includes distribution costs as well as market research, trade show attendance, advertising and public relations related to our products, and customer service expenses.

General and Administrative Expenses

General and administrative (“G&A”) expenses consist primarily of compensation, consulting, legal, human resources, information technology, accounting, insurance and general business expenses. Our G&A expenses have increased as a result of operating as a public company, especially as a result of hiring additional personnel and incurring greater director and officer insurance premiums, greater investor relations costs, and additional costs associated with accounting, legal, tax-related and other services associated with maintaining compliance with exchange listing and SEC requirements.

Research and Development Expenses

Research and development (“R&D”) expenses consist primarily of salaries and fringe benefits, laboratory supplies, clinical ~~trials~~studies and outside service costs. Our product development efforts primarily relate to new offerings in

~~Table of Contents~~

support of the ~~orthopedic/spinal repair~~orthobiologics market and activities associated with the development of aCanGaroo RM, our CanGaroo Envelope with antibiotics. Our future R&D expenses may increase as a result of additional work required to address the FDA’s questions in the NSE letter we recently received regarding our CanGaroo RM. We also conduct clinical ~~trials~~studies to validate the performance characteristics of our products and to capture patient data necessary to support our commercial efforts.

FiberCel Litigation Costs

FiberCel litigation costs consist primarily of legal fees and the estimated costs to resolve the outstanding FiberCel litigation cases offset by the estimated amounts recoverable under insurance, indemnity and contribution agreements for such costs.

Table of Contents

Results of Operations

Comparison of the Three Months Ended ~~September~~June 30, ~~2022~~2023 and ~~2021~~2022

Three Months Ended September 30,

2022

2021

Change 2021 / 2022

% of Net

% of Net

(in thousands, except percentages)

Amount

Sales

Amount

Sales

$

%

Net sales

$
12,389

100.0
%
$
11,485

100.0
%
$
904

7.9
%
Cost of goods sold

7,340

59.2
%

7,796

67.9
%

(456)

(5.8)
%
Gross profit

5,049

40.8
%

3,689

32.1
%

1,360

36.9
%
Sales and marketing

4,915

39.7
%

4,783

41.6
%

132

2.8
%
General and administrative

4,487

36.2
%

3,516

30.6
%

971

27.6
%
Research and development

1,966

15.9
%

2,289

19.9
%

(323)

(14.1)
%
FiberCel litigation costs

1,474

11.9
%

77

0.7
%

1,397

NM

Total operating expenses

12,842

103.7
%

10,665

92.9
%

2,177

20.4
%
Loss from operations

(7,793)

(62.9)
%

(6,976)

(60.7)
%

(817)

11.7
%
Interest expense

1,302

10.5
%

1,328

11.6
%

(26)

(2.0)
%
Other (income) expense, net

803

6.5
%

—

—
%

803

NM

Loss before provision of income taxes

(9,898)

(79.9)
%

(8,304)

(72.3)
%

(1,594)

19.2
%
Income tax expense

12

0.1
%

12

0.1
%

—

—
%
Net loss

$
(9,910)

(80.0)
%
$
(8,316)

(72.4)
%
$
(1,594)

19.2
%


	Three Months Ended June 30,
	2023				2022				Change 2022 / 2023
			% of Net				% of Net
(in thousands, except percentages)	Amount		Sales		Amount		Sales		$		%
Net sales	$	10,296	100.0	%	$	12,638	100.0	%	$	(2,342)	(18.5)	%
Cost of goods sold		9,316	90.5	%		7,740	61.2	%		1,576	20.4	%
Gross profit		980	9.5	%		4,898	38.8	%		(3,918)	(80.0)	%
Sales and marketing		3,618	35.1	%		5,406	42.8	%		(1,788)	(33.1)	%
General and administrative		4,005	38.9	%		4,711	37.3	%		(706)	(15.0)	%
Research and development		1,171	11.4	%		2,617	20.7	%		(1,446)	(55.3)	%
FiberCel litigation costs		1,271	12.3	%		346	2.7	%		925	NM
Total operating expenses		10,065	97.8	%		13,080	103.5	%		(3,015)	(23.1)	%
Loss from operations		(9,085)	(88.2)	%		(8,182)	(64.7)	%		(903)	11.0	%
Interest expense		1,524	14.8	%		1,204	9.5	%		320	26.6	%
Other (income) expense, net		—	—	%		—	—	%		—	NM
Loss before provision of income taxes		(10,609)	(103.0)	%		(9,386)	(74.3)	%		(1,223)	13.0	%
Income tax expense		12	0.1	%		12	0.1	%		—	—	%
Net loss	$	(10,621)	(103.2)	%	$	(9,398)	(74.4)	%	$	(1,223)	13.0	%

Net Sales

Net sales ~~increased $0.9~~information for our products is summarized as follows:


	Three Months Ended June 30,
	2023				2022
			% of Net				% of Net		Change 2022 / 2023
(in thousands, except percentages)	Amount		Sales		Amount		Sales		$		%
Products:
Device protection	$	2,221	21.6	%	$	2,244	17.8	%	$	(23)	(1.0)	%
Women's health		2,400	23.3	%		1,824	14.4	%		576	31.6	%
Orthobiologics		3,945	38.3	%		6,476	51.2	%	$	(2,531)	(39.1)	%
Cardiovascular		1,730	16.8	%		2,094	16.6	%	$	(364)	(17.4)	%
Total Net Sales	$	10,296	100.0	%	$	12,638	100.0	%	$	(2,342)	(18.5)	%

Total net sales decreased $2.3 million, or ~~7.9%~~18.5%, to ~~$12.4~~$10.3 million in the three months ended ~~September~~June 30, ~~2022~~2023 compared to ~~$11.5~~$12.6 million in the three months ended ~~September~~June 30, ~~2021. The improvement~~2022, with such decrease primarily attributable to the viable bone matrix recall and market withdrawal in ~~net sales was~~July 2023 described above. Such recall and market withdrawal, which impacted only our Orthobiologics business, necessitated the establishment of a product returns reserve and reversal of revenue totaling $3.0 million. Revenues from Women’s Health increased compared to the prior year’s second quarter due to volume growth ~~in net sales~~and revenues from Cardiovascular decreased slightly due to the commencement of our ~~Core Products~~distribution agreement with LeMaitre Vascular which provides for sales at a transfer price versus sales prior to such agreement being made at end-user pricing.

On June 19, 2023, Surgalign Holdings, Inc. (“Surgalign”) and certain of ~~$0.4~~its direct and indirect subsidiaries commenced voluntary proceedings under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. Total revenues generated by us from Surgalign during the three months ended June 30, 2023 and 2022 were $1.1 million and ~~Non-Core Products~~$1.3, respectively. Surgalign is in the process of ~~$0.5 million.~~selling its assets through the chapter 11 process. Our contract with Surgalign is not being assumed by the buyer of the relevant assets. Consequently, future revenues from our Surgalign distribution relationship are highly uncertain.

Table of Contents

Cost of Goods Sold

~~Net sales~~Cost of goods sold and gross margin percentage information for our ~~Core Products and Non-Core Products~~products is summarized as follows:


	Three Months Ended September 30,												Three Months Ended June 30,
	2022				2021								2023				2022
			% of Net				% of Net		Change 2021 / 2022						Gross				Gross		Change 2022 / 2023
(in thousands, except percentages)	Amount		Sales		Amount		Sales		$		%		Amount		Margin %		Amount		Margin %		$		%
Products:
Core Products	$	8,949	72.2	%	$	8,588	74.8	%	$	361	4.2	%
Non-Core Products		3,440	27.8	%		2,897	25.2	%		543	18.7	%
Total Net Sales	$	12,389	100.0	%	$	11,485	100.0	%	$	904	7.9	%
Device protection													$	723	67.4	%	$	814	63.7	%	$	(91)	3.7	%
Women's health														1,493	37.8	%		820	55.0	%		673	(17.3)	%
Orthobiologics														5,678	(43.9)	%		4,834	25.4	%		844	(69.3)	%
Cardiovascular														573	66.9	%		423	79.8	%		150	(12.9)	%
Cost of goods sold, excluding intangible asset amortization														8,467	17.8	%		6,891	45.5	%		1,576	(27.7)	%
Intangible asset amortization expense														849	(8.2)	%		849	(6.7)	%		—	(1.5)	%
Total Cost of Goods Sold													$	9,316	9.5	%	$	7,740	38.8	%	$	1,576	(29.2)	%

~~Net sales generated by our Core Products~~Total cost of goods sold increased ~~$0.4~~$1.6 million ~~or 4.2%,~~ to ~~$8.9~~$9.3 million in the three months ended ~~September~~June 30, ~~2022~~2023 compared to ~~$8.6~~$7.7 million in the three months ended ~~September~~June 30, ~~2021.~~2022. Gross margin was 9.5% in the three months ended June 30, 2023 compared to 38.8% in the three months ended June 30, 2022. Gross margin, excluding intangible asset amortization, was 17.8% in the three months ended June 30, 2023 compared to 45.5% in the three months ended June 30, 2022. The ~~Core Products~~decline in gross margin was due to the gross margin impact of the viable bone matrix recall and market withdrawal in July 2023 which, including both the revenue reversal noted above and inventory writedown described in Note 8 to the condensed consolidated financial statements, totaled $5.0 million causing a decrease in gross margin percentage of 35.4%. With respect to the individual product segments, the gross margin of Device Protection improved in the three months ended June 30, 2023 compared to the three months ended June 30, 2022 due to operational efficiencies in the current year causing lower costs to manufacture the product. The gross margin of Women’s Health declined due to non-recurring production issues and the gross margin of the Cardiovascular business declined due to the commencement of the LeMaitre Vascular distribution agreement described above.

Operating Expenses

Sales and Marketing

Sales and marketing expenses increased $1.8 million, or 33.1%, to $3.6 million in the three months ended June 30, 2023 compared to $5.4 million in the three months ended June 30, 2022. As a percentage of sales, sales and marketing expenses decreased to 35.1% in the three months ended June 30, 2023 from 42.8% in the three months ended June 30, 2022. The decrease in expense was largely attributable to the previously announced reduction in force which occurred in the first quarter of 2023 and primarily impacted certain members of sales and marketing management.

General and Administrative

G&A expenses decreased $0.7 million, or 15.0%, to $4.0 million in the three months ended June 30, 2023 compared to $4.7 million in the three months ended June 30, 2022. As a percentage of net sales, ~~growth can be attributed~~G&A expenses increased to ~~sales volume increases~~38.9% in the three months ended June 30, 2023 from 37.3% in the three months ended June 30, 2022. The decrease in expense was primarily due to declines in the cost of insurance and lower equity compensation expense.

Research and Development

R&D expenses decreased to $1.2 million in the three months ended June 30, 2023 compared to $2.6 million in the three months ended June 30, 2022. We continue to focus our R&D efforts primarily on the development of our CanGaroo ~~and SimpliDerm products.~~RM Antibacterial Envelope. Such related costs were less in the second quarter of 2023 versus the prior year’s

Table of Contents

Net sales generated by our Non-Core Products increased $0.5 million, or 18.7%, to $3.4 million in the three months ended September 30, 2022 compared to $2.9 million in the three months ended September 30, 2021. The increase was primarily driven by a growth in the revenue from several ~~contract manufacturing customers~~.

~~Cost of Goods Sold~~

Cost of goods sold decreased $0.5 million, or 5.8%, to $7.3 million in the three months ended September 30, 2022 compared to $7.8 million in the three months ended September 30, 2021, and included, in each case, $0.8 million of intangible asset amortization expenses. Gross margin in the three months ended September 30, 2022 was 40.8%, an increase from 32.1% in the corresponding prior year period. Gross margin, excluding intangible asset amortization, in the three months ended September 30, 2022 was 47.6%, an increase from 39.5% in the corresponding prior year period. Gross margin, excluding intangible asset amortization, is a non-GAAP financial measure. See "Non-GAAP Financial Measures” for a discussion regarding our use of gross margin, excluding intangible asset amortization, including its limitations and a reconciliationcomparable period due to the ~~most directly comparable GAAP financial measure. The increase in gross margin~~reduction of efforts needed and ~~decrease in cost of goods sold was primarily due to recent production efficiencies and improved inventory management in the three months ended September 30, 2022.~~

~~Operating Expenses~~

~~Sales and Marketing~~

~~Sales and marketing~~ expenses increased $0.1 million, or 2.8%, to $4.9 million in the three months ended September 30, 2022 compared to $4.8 million in the three months ended September 30, 2021. As a percentage of sales, sales and marketing expenses declined to 39.7% in the three months ended September 30, 2022 from 41.6% in the three months ended September 30, 2021. The decreaseincurred as a percentage of sales was the result of the growth during the three months ended September 30, 2022 of revenues from sales to contract manufacturing customers as such revenues have lower selling costs than our sales directly to end users.

~~General and Administrative~~

G&A expenses increased $1.0 million, or 27.6%, to $4.5 million in the three months ended September 30, 2022 compared to $3.5 million in the three months ended September 30, 2021. As a percentage of net sales, G&A expenses increased to 36.2% in the three months ended September 30, 2022 from 30.6% in the three months ended September 30, 2021. The increase in expense was primarily due to certain non-recurring charges associated with legal fees on various corporate matters and the Chief Executive Officer transition described in Note 4 to the condensed consolidated financial statements.

~~Research and Development~~

~~R&D expenses decreased to $2.0 million in the three months ended September 30, 2022 compared to $2.3 million in the three months ended September 30, 2021. We continue to focus our R&D efforts on~~ the development of our pipeline products and the decline in R&D expenses in the three months ended September 30, 2022 was largely attributable to the lessening of work needed to finalize the development and testing of our CanGaroo with antibiotics.progresses toward anticipated completion.

FiberCel Litigation Costs

FiberCel litigation costs increased to ~~$1.5~~$1.3 million in the three months ended ~~September~~June 30, ~~2022~~2023 compared to ~~$0.1~~$0.3 million in the three months ended ~~September~~June 30, ~~2021.~~2022. The increase in expense was primarily due to the ~~settlements reached~~establishment of the Contingent Liability for FiberCel litigation in ~~a significant number~~the third quarter of 2022 and the legal defense costs incurred as the FiberCel ~~Litigation~~ cases progress. FiberCel litigation costs in the three months ended ~~September~~June 30, 2022 ~~as well as the estimation~~were comprised only of contingent liabilities for the unsettled cases. The total of such settlement and estimated settlement values was recorded (net of estimated insurance, indemnity and contribution agreement recoveries) in the three months ended September 30, 2022.legal fees incurred See further discussion in Note 8 to condensed consolidated financial statements included elsewhere in this Quarterly Report.

~~Table of Contents~~

Interest Expense

Interest expense was approximately ~~$1.3~~$1.5 million in both the three months ended September 30, 2022 and 2021. See “- Liquidity and Capital Resources - Credit Facilities” below for a discussion of our borrowings related to these interest expenses and Note 7 to the condensed consolidated financial statements included elsewhere in this Quarterly Report for a description of our Revenue Interest Obligation and the interest expense related thereto.

~~Other (Income) Expense, net~~

~~Other (income) expense, net was approximately $0.8 million of expense~~ in the three months ended ~~September~~June 30, ~~2022. Such other expense relates~~2023 compared to ~~our debt refinancing in August 2022 and the associated prepayment fees, payment of unaccrued exit fees and write-off of unamortized deferred financing costs which collectively~~ ~~resulted in a loss of~~ $1.2 million. Such loss was offset by other income of $0.4 million related to the forgiveness of interest accrued on the promissory note to a tissue supplier upon repayment of such note in August 2022. See Note 6 to the accompanying condensed consolidated statements of operations for the three and nine months ended September 30, 2022 for further discussion of these transactions.

~~Comparison of the Nine Months Ended September 30, 2022 and 2021~~

Nine Months Ended September 30,

2022

2021

Change 2021 / 2022

% of Net

% of Net

(in thousands, except percentages)

Amount

Sales

Amount

Sales

$

%


Net sales

$
36,522

100.0
%
$
36,529

100.0
%
$
(7)

(0.0)
%

Cost of goods sold

22,294

61.0
%

20,897

57.2
%

1,397

6.7
%

Gross profit

14,228

39.0
%

15,632

42.8
%

(1,404)

(9.0)
%

Sales and marketing

15,139

41.5
%

14,285

39.1
%

854

6.0
%

General and administrative

13,223

36.2
%

10,501

28.7
%

2,722

25.9
%

Research and development

6,855

18.8
%

5,890

16.1
%

965

16.4
%

FiberCel litigation costs

1,908

5.2
%

226

0.6
%

1,682

NM

Total operating expenses

37,125

101.7
%

30,902

84.6
%

6,223

20.1
%

Loss from operations

(22,897)

(62.7)
%

(15,270)

(41.8)
%

(7,627)

49.9
%

Interest expense

3,721

10.2
%

4,034

11.0
%

(313)

(7.8)
%

Other (income) expense, net

803

2.2
%

(3,579)

(9.8)
%

4,382

NM

Loss before provision of income taxes

(27,421)

(75.1)
%

(15,725)

(43.0)
%

(11,696)

74.4
%

Income tax expense

36

0.1
%

43

0.1
%

(7)

(16.3)
%

Net loss

$
(27,457)

(75.2)
%
$
(15,768)

(43.2)
%
$
(11,689)

74.1
%

~~Net Sales~~

~~Net sales were $36.5 million in both the nine months ended September 30, 2022 and 2021. Net sales information for our Core Products and Non-Core Products is summarized as follows:~~

Nine Months Ended September 30,

2022

2021

% of Net

% of Net

Change 2021 / 2022

(in thousands, except percentages)

Amount

Sales

Amount

Sales

$

%


Products:













Core Products

$
26,141

71.6
%
$
29,230

80.0
%
$
(3,089)

(10.6)
%

Non-Core Products

10,381

28.4
%

7,299

20.0
%

3,082

42.2
%

Total Net Sales

$
36,522

100.0
%
$
36,529

100.0
%
$
(7)

(0.0)
%

~~Net sales generated by our Core Products declined $3.1 million, or 10.6%, to $26.1~~ million in the ~~nine~~three months ended ~~September~~June 30, 2022 compared to $29.2 million in the nine months ended September 30, 2021. The decrease in Core Products net sales can be attributed to the cessation of purchases by Medtronic of FiberCel following our recall of a single

~~Table of Contents~~

lot of FiberCel in June 2021 partially offset by sales volume increases in our CanGaroo and SimpliDerm products. Sales of FiberCel to Medtronic were $4.9 million in the nine months ended September 30, 2021.

Net sales generated by our Non-Core Products increased $3.1 million, or 42.2%, to $10.4 million in the nine months ended September 30, 2022 compared to $7.3 million in the nine months ended September 30, 2021.2022. The increase was ~~primarily driven by a growth in the revenue from several~~ ~~contract manufacturing customers.~~

~~Cost of Goods Sold~~

Cost of goods sold increased $1.4 million, or 6.7%, to $22.3 million in the nine months ended September 30, 2022 compared to $20.9 million in the nine months ended September 30, 2021, and included, in each case, $2.5 million of intangible asset amortization expenses. Gross margin in the nine months ended September 30, 2022 was 39.0%, a decrease from 42.8% in the corresponding prior year period. Gross margin, excluding intangible asset amortization, in the nine months ended September 30, 2022 was 45.9%, a decline from 49.8% in the corresponding prior year period. Gross margin, excluding intangible asset amortization, is a non-GAAP financial measure. See "Non-GAAP Financial Measures” for a discussion regarding our use of gross margin, excluding intangible asset amortization, including its limitations and a reconciliation to the most directly comparable GAAP financial measure. The decrease in gross margin and increase to cost of goods sold was primarily due to product mix (higher Non-Core revenues in 2022 with lower gross margins).

~~Operating Expenses~~

~~Sales and Marketing~~

Sales and marketing expenses increased $0.8 million, or 6.0%, to $15.1 million in the nine months ended September 30, 2022 compared to $14.3 million in the nine months ended September 30, 2021. As a percentage of sales, sales and marketing expenses grew to 41.5% in the nine months ended September 30, 2022 from 39.1% in the nine months ended September 30, 2021. The increase as a percentage of sales was the result of higher stock-based compensation and travel costs related to our sales force.

~~General and Administrative~~

G&A expenses increased $2.7 million, or 25.9%, to $13.2 million in the nine months ended September 30, 2022 compared to $10.5 million in the nine months ended September 30, 2021. As a percentage of net sales, G&A expenses increased to 36.2% in the nine months ended September 30, 2022 from 28.7% in the nine months ended September 30, 2021. The increase in expense was primarily due to higher stock-based compensation as well as non-recurring charges totaling $1.7 million associated with legal fees on various corporate matters and the Chief Executive Officer transition described in Note 4 to the condensed consolidated financial statements.

~~Research and Development~~

R&D expenses increased to $6.9 million in the nine months ended September 30, 2022 compared to $5.9 million in the nine months ended September 30, 2021. We continue to focus our R&D efforts on the development of our pipeline products and the growth in R&D expenses in the nine months ended September 30, 2022 was largely attributable to the work performed on the final development and testing of our CanGaroo with antibiotics.

~~FiberCel Litigation Costs~~

FiberCel litigation costs increased to $1.9 million in the nine months ended September 30, 2022 compared to $0.2 million in the nine months ended September 30, 2021. The increase in expense was primarily due to the ~~settlements reached in a significant number of FiberCel Litigation cases~~higher principal outstanding and interest rates incurred by us on our existing debt, the SWK Loan Facility, as compared to the debt outstanding in the ~~nine~~three months ~~ended September~~ending June 30, 2022, ~~as well as~~which consisted primarily of the estimation of contingent liabilities for the unsettled cases. The total of such settlement and estimated settlement values was recorded (net of estimated insurance, indemnity and contribution agreement recoveries) in the nine months ended September 30, 2022. See further discussion in Note 8 to condensed consolidated financial statements included elsewhere in this Quarterly Report.

~~Table of Contents~~

~~Interest Expense~~

Interest expense was approximately $3.7 million in the nine months ended September 30, 2022 compared to $4.0 million in the nine months ended September 30, 2021. The decrease was due to lower draws on our formerly outstanding MidCap Credit Facility (as defined, and further described, in Note 6 to the condensed consolidated financial statements included elsewhere in this Quarterly Report) and lower outstanding principal on our formerly outstanding MidCap Loan Facility ~~(as defined,~~ and ~~further described, in Note 6 to the condensed consolidated financial statements included elsewhere in this Quarterly Report) due to the commencement of principal payments in August 2021.~~MidCap Credit Facility. See “ - Liquidity and Capital Resources - Credit Facilities” below for a further discussion of these debt agreements and Note 6 to the condensed consolidated financial statements included elsewhere in this Quarterly Report.

~~Other (Income) Expense, net~~

Comparison of the Six Months Ended June 30, 2023 and 2022

~~Other (income) expense,~~


	Six Months Ended June 30,
	2023				2022				Change 2022 / 2023
			% of Net				% of Net
(in thousands, except percentages)	Amount		Sales		Amount		Sales		$		%
Net sales	$	23,346	100.0	%	$	24,133	100.0	%	$	(787)	(3.3)	%
Cost of goods sold		16,035	68.7	%		14,954	62.0	%		1,081	7.2	%
Gross profit		7,311	31.3	%		9,179	38.0	%		(1,868)	(20.4)	%
Sales and marketing		8,974	38.4	%		10,224	42.4	%		(1,250)	(12.2)	%
General and administrative		7,684	32.9	%		8,736	36.2	%		(1,052)	(12.0)	%
Research and development		2,974	12.7	%		4,889	20.3	%		(1,915)	(39.2)	%
FiberCel litigation costs		3,182	13.6	%		434	1.8	%		2,748	NM
Total operating expenses		22,814	97.7	%		24,283	100.6	%		(1,469)	(6.0)	%
Loss from operations		(15,503)	(66.4)	%		(15,104)	(62.6)	%		(399)	(2.6)	%
Interest expense		3,068	13.1	%		2,419	10.0	%		649	26.8	%
Loss before provision of income taxes		(18,571)	(79.5)	%		(17,523)	(72.6)	%		(1,048)	(6.0)	%
Income tax expense		24	0.1	%		24	0.1	%		—	—	%
Net loss	$	(18,595)	(79.6)	%	$	(17,547)	(72.7)	%	$	(1,048)	(6.0)	%

Table of Contents

Net Sales

Net sales information for our products is summarized as follows:


	Six Months Ended June 30,
	2023				2022
			% of Net				% of Net		Change 2022 / 2023
(in thousands, except percentages)	Amount		Sales		Amount		Sales		$		%
Products:
Device protection	$	4,571	19.6	%	$	4,296	17.8	%	$	275	6.4	%
Women's health		4,695	20.1	%		3,458	14.3	%		1,237	35.8	%
Orthobiologics		10,603	45.4	%		12,720	52.7	%	$	(2,117)	(16.6)	%
Cardiovascular		3,477	14.9	%		3,659	15.2	%	$	(182)	(5.0)	%
Total Net Sales	$	23,346	100.0	%	$	24,133	100.0	%	$	(787)	(3.3)	%

Total net ~~was approximately~~sales decreased $0.8 million, ~~of expense~~or 3.3%, to $23.3 million in the ~~nine~~six months ended ~~September~~June 30, 2023 compared to $24.1 million in the six months ended June 30, 2022, with such decrease primarily attributable to the viable bone matrix recall and market withdrawal in July 2023 described above. Such recall and market withdrawal, which impacted only our Orthobiologics business, necessitated the establishment of a product returns reserve and reversal of revenue totaling $3.0 million. Revenues from Device Protection and Women’s Health increased compared to the corresponding period of the prior year due to volume growth and revenues from Cardiovascular decreased slightly due to the commencement of our distribution agreement with LeMaitre Vascular which provides for sales at a transfer price versus sales prior to such agreement being made at end-user pricing.

On June 19, 2023, Surgalign Holdings, Inc. (“Surgalign”) and certain of its direct and indirect subsidiaries commenced voluntary proceedings under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. Total revenues generated by us from Surgalign during the six months ended June 30, 2023 and 2022 were $2.3 million and $2.5, respectively. Surgalign is in the process of selling its assets through the chapter 11 process. Our contract with Surgalign is not being assumed by the buyer of the relevant assets. Consequently, future revenues from our Surgalign distribution relationship are highly uncertain.

Cost of Goods Sold

Cost of goods sold and gross margin percentage information for our products is summarized as follows:


	Six Months Ended June 30,
	2023				2022
			Gross				Gross		Change 2022 / 2023
(in thousands, except percentages)	Amount		Margin %		Amount		Margin %		$		%
Products:
Device protection	$	1,277	72.1	%	$	1,547	64.0	%	$	(270)	8.1	%
Women's health		2,736	41.7	%		1,780	48.5	%		956	(6.8)	%
Orthobiologics		9,378	11.6	%		9,175	27.9	%		203	(16.3)	%
Cardiovascular		945	72.8	%		753	79.4	%		192	(6.6)	%
Cost of goods sold, excluding intangible asset amortization		14,336	38.6	%		13,255	45.1	%		1,081	(6.5)	%
Intangible asset amortization expense		1,699	(7.3)	%		1,699	(7.0)	%		—	(0.2)	%
Total Cost of Goods Sold	$	16,035	31.3	%	$	14,954	38.0	%	$	1,081	(6.7)	%

Total cost of goods sold increased $1.1 million to $16.0 million in the six months ended June 30, 2023 compared to $15.0 million in the six months ended June 30, 2022. ~~Such other expense relates~~Gross margin was 31.3% in the six months ended June 30, 2023 compared to ~~our debt refinancing~~38.0% in ~~August 2022 and~~ the ~~associated prepayment fees, payment of unaccrued exit fees and~~six months ended June 30, 2022. Gross margin, excluding intangible asset amortization, was 38.6% in the ~~write-off of unamortized deferred financing costs, which collectively~~ ~~resulted~~six months ended June 30, 2023 compared to 45.1% in ~~a loss of $1.2 million. Such loss~~the six months ended June 30, 2022. The decline in gross margin was ~~offset by other income of $0.4 million related~~due to the ~~forgiveness~~gross margin impact of ~~interest accrued on~~ the ~~promissory note to a tissue supplier upon repayment~~viable bone matrix recall and market withdrawal in July 2023

Table of ~~such note~~Contents

which, including both the revenue reversal noted above and inventory writedown described in ~~August 2022. See~~ Note ~~6 to the accompanying condensed consolidated statements of operations for the three and nine months ended September 30, 2022 for further discussion of these transactions.~~

Other (income) expense, net was approximately $3.6 million of income in the nine months ended September 30, 2021. Such other income relates to the forgiveness of our PPP Loan totaling approximately $3.0 million and the Company’s receipt of $550,000 in satisfaction of a 2018 settlement with Keralink. For further discussion on these items, see Notes 6 and 108 to the condensed consolidated financial statements, ~~shown~~totaled $5.0 million causing a decrease in gross margin percentage of 15.4%. With respect to the individual product segments, the gross margin of Device Protection improved in the six months ended June 30, 2023 compared to the six months ended June 30, 2022 due to operational efficiencies in the current year causing lower costs to manufacture the product. The gross margin of Women’s Health declined due to non-recurring production issues and the gross margin of the Cardiovascular business declined due to the commencement of the LeMaitre Vascular distribution agreement described above.

Operating Expenses

Sales and Marketing

Sales and marketing expenses decreased $1.2 million, or 12.2%, to $9.0 million in the six months ended June 30, 2023 compared to $10.2 million in the six months ended June 30, 2022. As a percentage of sales, sales and marketing expenses decreased to 38.4% in the six months ended June 30, 2023 from 42.4% in the six months ended June 30, 2022. The decrease in expense was largely attributable to the previously announced reduction in force which occurred in the first quarter of 2023 and primarily impacted certain members of sales and marketing management.

General and Administrative

G&A expenses decreased $1.0 million, or 12.0%, to $7.7 million in the six months ended June 30, 2023 compared to $8.7 million in the six months ended June 30, 2022. As a percentage of net sales, G&A expenses decreased to 32.9% in the six months ended June 30, 2023 from 36.2% in the six months ended June 30, 2022. The decrease in expense was primarily due to declines in the cost of insurance and lower equity compensation expense.

Research and Development

R&D expenses decreased to $3.0 million in the six months ended June 30, 2023 compared to $4.9 million in the six months ended June 30, 2022. We continue to focus our R&D efforts primarily on the development of our CanGaroo RM Antibacterial Envelope. Such related costs were slightly less in the first six months of 2023 versus the prior year’s comparable period due to the reduction of efforts needed and expenses incurred as the development progresses toward anticipated completion.

FiberCel Litigation Costs

FiberCel litigation costs increased to $3.2 million in the six months ended June 30, 2023 compared to $0.4 million in the six months ended June 30, 2022. The increase in expense was primarily due to the establishment of the Contingent Liability for FiberCel litigation in the third quarter of 2022 and the continued evaluation of such liability and legal defense costs incurred as the FiberCel cases progress. FiberCel litigation costs in the six months ended June 30, 2022 were comprised only of legal fees incurred. See further discussion in Note 8 to condensed consolidated financial statements included elsewhere in this Quarterly Report.

Interest Expense

Interest expense was approximately $3.1 million in the six months ended June 30, 2023 compared to $2.4 million in the six months ended June 30, 2022. The increase was due to the higher principal outstanding and interest rates incurred by us on our existing debt, the SWK Loan Facility, as compared to the debt outstanding in the six months ending June 30, 2022, which consisted primarily of the MidCap Loan Facility and MidCap Credit Facility. See “ - Liquidity and Capital Resources - Credit Facilities” below for a further discussion of these debt agreements and Note 6 to the condensed consolidated financial statements included elsewhere in this Quarterly Report.

Table of Contents

Non-GAAP Financial Measures

This Quarterly Report presents our gross margin, excluding intangible asset amortization, for the three and ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 and ~~2021.~~2022. We calculate gross margin, excluding intangible asset amortization, as gross profit, excluding amortization expense relating to intangible assets we acquired in the CorMatrix Acquisition, divided by net sales. Gross margin, excluding intangible asset amortization, is a supplemental measure of our performance, is not defined by or presented in accordance with U.S. generally accepted accounting principles (“GAAP”), has limitations as an analytical tool and should not be considered in isolation or as an alternative to our GAAP gross margin, gross profit or any other financial performance measure presented in accordance with GAAP. We present gross margin, excluding intangible asset amortization, because we believe that it provides meaningful supplemental information regarding our operating performance by removing the impact of amortization expense, which is not indicative of our overall operating performance. We believe this provides our management and investors with useful information to facilitate period-to-period comparisons of our operating results. Our management uses this metric in assessing the health of our business and our operating performance, and we believe investors’ understanding of our operating performance is similarly enhanced by our presentation of this metric. In addition, other companies, including companies in our industry, may use other measures to evaluate their performance, which could reduce the usefulness of this non-GAAP financial measure as a tool for comparison.

~~Table of Contents~~

The following table presents a reconciliation of our gross margin, excluding intangible asset amortization, for the three and ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 and ~~2021~~2022 to the most directly comparable GAAP financial measure, which is our GAAP gross margin (in thousands).


	Three Months Ended						Nine Months Ended						Three Months Ended						Six Months Ended
	September 30,						September 30,						June 30,						June 30,
	2022			2021			2022			2021			2023			2022			2023			2022
Net sales	$	12,389		$	11,485		$	36,522		$	36,529		$	10,296		$	12,638		$	23,346		$	24,133
Cost of goods sold		7,340			7,796			22,294			20,897			9,316			7,740			16,035			14,954
Gross profit		5,049			3,689			14,228			15,632			980			4,898			7,311			9,179
Intangible asset amortization expense		849			849			2,548			2,548			849			849			1,698			1,698
Gross profit, excluding intangible asset amortization	$	5,898		$	4,538		$	16,776		$	18,180		$	1,829		$	5,747		$	9,009		$	10,877
Gross margin		40.8	%		32.1	%		39.0	%		42.8	%		9.5	%		38.8	%		31.3	%		38.0	%
Gross margin, excluding intangible asset amortization		47.6	%		39.5	%		45.9	%		49.8	%		17.8	%		45.5	%		38.6	%		45.1	%

Seasonality

Historically, we have experienced seasonality, with lower sales in our first and second quarters and higher sales in our fourth quarter, and we expect this trend to continue. We have experienced and may in the future experience, higher sales in the fourth quarter as a result of hospitals in the United States increasing their purchases of our products to coincide with the end of their budget cycles. Satisfaction of patient deductibles throughout the course of the year also results in increased sales later in the year, once patients have paid their annual insurance deductibles in full, which reduces their out-of-pocket costs. Conversely, our first quarter generally has lower sales than the preceding fourth quarter as patient deductibles are re-established with the new year, which increases their out-of-pocket costs.

Liquidity and Capital Resources

As of ~~September~~June 30, ~~2022,~~2023, we had cash of approximately ~~$8.1~~$9.3 million. In August 2022, we refinanced our debt as described below under “— Credit Facilities.” Since inception, we have financed our operations primarily through private placements of our convertible preferred stock, amounts borrowed under our credit facilities, sales of our products and more recently, proceeds from our IPO and a private placement of our common stock. Our historical cash outflows have primarily been associated with acquisitions and integration, manufacturing and administrative costs, general and marketing, research and development, clinical activity, purchase of property and equipment used in the production activities of our Richmond, California facility and investing in our commercial infrastructure through our direct sales force and our commercial partners in order to expand our presence and to promote awareness and adoption of our products. As of ~~September~~June 30, ~~2022,~~2023, our accumulated deficit was ~~$132.5~~$156.6 million.

~~On December 8, 2021, we closed on a private investment in public equity (PIPE) financing, thereby receiving net proceeds~~33

Table of approximately $13.8 million, after deducting offering costs. The PIPE investors purchased an aggregate of 2,122,637 shares of the Company’s Class A common stock and an aggregate of 1,179,244 shares of the Company’s Class B common stock (which are convertible on a one-for-one basis into shares of Class A common stock), in each case, at a price of $4.24 per share.Contents

We expect our losses to continue for the foreseeable future and these losses will continue to have an adverse effect on our financial position. Because of the numerous risks and uncertainties associated with our commercialization and development efforts, we are unable to predict when we will become profitable, and we may never become profitable. Our inability to achieve and then maintain profitability would negatively affect our business, financial condition, results of operations and cash flows.

~~Table of Contents~~

the SWK Loan Facility (described below under “—Credit Facilities”), issuances of additional equity and cash generated from expected future sales will be sufficient to meet our anticipated operating needs through twelve months from the financial statement issuance date. Due to these factors, there is substantial doubt about our ability to continue as going concern within one year after the issuance of the financial statements.

Cash Flows for the ~~Nine~~Six Months Ended ~~September~~June 30, ~~2022~~2023 and ~~2021~~2022



					Six Months Ended
	Nine Months Ended September 30,				June 30,
	2022		2021		2023		2022

	(in thousands)				(in thousands)
Net cash used in:
Operating activities	$	(16,189)	$	(9,059)	$	(7,555)	$	(10,674)
Investing activities		(406)		(344)		(267)		(289)
Financing activities		(5,732)		(7,503)		129		(2,954)
Net decrease in cash	$	(22,327)	$	(16,906)	$	(7,693)	$	(13,917)

Net Cash Used in Operating Activities

Net cash used in operating activities for the ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 was ~~$16.2~~$7.6 million compared to ~~$9.1~~$10.7 million for the ~~nine~~six months ended ~~September~~June 30, ~~2021.~~2022. The year-over-year ~~increase~~decrease was primarily due to a ~~gain on extinguishment~~higher net loss (after adjustment for non-cash charges and gains) as well as the timing of ~~debt in the three months ended September 30, 2021 versus a loss experienced in the three months ended September 30, 2022. Additionally, due~~certain annual insurance prepayments and reduction to ~~timing, accounts payable increases in the current period increased cash and~~receivables offset ~~a portion of the cash used in operating cash activities when compared to the prior period.~~by inventory builds.

Net Cash Used in Investing Activities

Net cash used in investing activities for the ~~nine~~six months ended ~~September~~June 30, 2023 and 2022 was ~~$0.4 million compared to~~ $0.3 ~~million for the nine months ended September 30, 2021.~~million. In both periods, the use of cash related to the purchase of property and equipment, the majority of which were used in the production activities of our Richmond, California facility.

Net Cash Used in Financing Activities

Net cash provided by financing activities for the six months ended June 30, 2023 was $0.1 million compared to net cash used in financing activities ~~for the nine months ended September 30, 2022 was $5.7 million compared to $7.5~~of $3.0 million for the ~~nine~~six months ended ~~September~~June 30, ~~2021.~~2022. The year-over-year net decrease was caused primarily by payments made in the ~~net cash infusion from~~2022 period related to our Revenue Interest Obligation with no such payments having been made in the ~~proceeds~~2023 period due to ongoing restructuring discussions with Ligand (as defined below).

Table of ~~the August 2022 debt refinancing, less all debt repayments and refinancing costs incurred during the nine months ended September 30, 2022. See “Credit Facilities” below for further discussion.~~Contents

Credit Facilities

General

On August 10, 2022 (the “Closing Date”), we entered into a senior secured term loan facility with SWK Funding LLC (“SWK”), as agent, and other lenders party thereto ~~(the~~(as amended and modified subsequent to the Closing Date, the “SWK Loan Facility”) for an aggregate principal amount of $25 ~~million, with~~million. An initial draw of $21 million drawn was made on the Closing Date ~~(the “Initial Term Loan”) and~~with the additional $4 million ~~that becomes available, subject to~~drawn on December 14, 2022 upon satisfaction of the ~~achievement of specified operational and financial metrics by September 30, 2023 (the “Additional Term Loan”).~~amended terms enabling such receipt. The SWK Loan Facility also allows for the establishment of a separate, new asset-based revolving loan facility of up to $8 million, which had not been entered into ~~as of September 30, 2022. We~~to date. In connection with the August 2022 debt refinancing, we used $16 million of the proceeds of the SWK Loan Facility to pay all outstanding obligations on the formerly outstanding MidCap Loan Facility and MidCap Credit Facility. Such payment included (i) $12.8 million to repay all outstanding principal and accrued interest on the MidCap Loan Facility, (ii) $1.7 million to pay the prepayment and exit fees on the MidCap Loan Facility and (iii) $1.5 million to repay the outstanding balance, accrued interest and exit fees on the MidCap Credit Facility.

As of ~~September~~June 30, ~~2022,~~2023, we had ~~$20.0~~$24.9 million of indebtedness outstanding under our SWK Loan Facility, ~~(net~~with such balance being net of ~~$1.0~~$0.9 million of unamortized discount and deferred financing ~~costs).~~

~~Table~~costs, but increased by capitalized PIK Interest (as defined below) of ~~Contents~~$0.9 million since November 2022.

Interest Rates

All of the SWK Loan Facility borrowings take the form of Secured Overnight Financing Rate (“SOFR”) loans and will bear interest at a rate per annum equal to the sum of an applicable margin of (i) ~~8.75%~~7.75% and the “Term SOFR Rate” (based upon an interest period of 3 months), or (ii) if we have elected the PIK Interest option (as defined below), ~~4.75%~~3.75% and the “Term SOFR Rate.” We may elect a portion of the interest due, to be paid in-kind at a rate per annum of 4.5% (“PIK Interest”), and such election may be made (x) until November 15, 2024 if ~~the~~certain profitability and regulatory conditions ~~to draw the Additional Term Loan~~(“Extension Conditions”) have not been met, or ~~(y)~~until November 17, 2025 if such conditions ~~to draw the Additional Term Loan~~ have been ~~satisfied, until November 17, 2025.~~satisfied. The “Term SOFR Rate” is subject to a floor of 2.75%.

Mandatory Prepayments

The SWK Loan Facility Agreement requires certain mandatory prepayments, subject to certain exceptions, with: (1) 100% of any net casualty proceeds in excess of $250,000 and (2) for non-ordinary course asset sales, an amount equal to the difference between (x) the proportion of divested gross profit (as defined in the SWK Loan Facility Agreement) to the Company’s total gross profit (as defined in the SWK Loan Facility Agreement) multiplied by the outstanding loans under the SWK Loan Facility, and (y) the difference between $1,000,000 and the aggregate sale proceeds of any assets previously sold during the fiscal year. No such mandatory prepayments were required during the three ~~and nine~~ months ended ~~September~~June 30, ~~2022.~~2023.

Optional Prepayment

The SWK Loan Facility Agreement also includes an exit fee equal ~~to: (i) if such prepayment occurs~~to 6.5% of the aggregate principal amount funded prior to ~~the first anniversary of the Closing Date,~~termination, and prepayment penalties that are equal to: (i) 2% of the aggregate principal amount funded prior to the termination plus remaining unpaid interest payments scheduled to be paid during the first year of the loan if such prepayment occurs prior to the first anniversary of the Closing Date, or (ii) 2% of the aggregate principal amount funded prior to termination if such prepayment occurs after the first anniversary of the Closing Date but prior to the second anniversary of the Closing ~~Date, 2% of the aggregate principal amount funded prior to termination.~~Date.

Amortization and Final Maturity

The SWK Loan Facility matures on August 10, 2027 and accrues interest, payable quarterly in arrears. Principal amortization of the SWK Loan Facility starts on November 15, 2024, which amortization may be extended to November 17, 2025 if ~~conditions to draw~~ the ~~Additional Term~~Extension Conditions (as defined in the SWK Loan Facility Agreement) have been satisfied. Principal payments during the amortization period will be limited based on revenue-based caps. As of ~~September~~June 30, ~~2022,~~2023, quarterly

Table of Contents

principal payments are scheduled to begin on November 15, 2024, in an amount equal to 5% of the ~~Initial Term Loan~~outstanding principal on such principal payment commencement date with the balance paid at maturity.

Security

All obligations under the SWK Loan Facility are, and any future guarantees of those obligations will be, secured by, among other things, and in each case subject to certain exceptions, a first priority lien on and security interest in, upon, and to all of our assets, whether now owned or hereafter acquired, wherever located.

Covenants and Other Matters

The SWK Loan Facility Agreement that governs the SWK Loan Facility contains a number of covenants that, among other things and subject to certain exceptions, restrict our ability to:

●

incur additional indebtedness;

●

incur certain liens;

●

pay dividends or make other distributions on equity interests;

●

redeem, repurchase or refinance subordinated indebtedness;

~~Table of Contents~~

●

consolidate, merge or sell or otherwise dispose of their assets;

●

make investments, loans, advances, guarantees and acquisitions;

●

enter into transactions with affiliates;

●

amend or modify their governing documents;

●

amend or modify certain material agreements; and

●

alter the business conducted by them and their subsidiaries.

In addition, the SWK Loan Facility Agreement contains two financial covenants. The first covenant, which is measured quarterly, requires us to achieve a specified Minimum Aggregate Revenue (as defined in the SWK Loan Facility Agreement) for the preceding 12-month period. The second covenant requires us to maintain a minimum liquidity (as defined in the SWK Loan Facility Agreement) of $5.0 million until ~~November 21,~~December 16, 2022 ~~(as amended from the previous compliance date of November 10, 2022, which had been previously amended from the compliance date of October 10, 2022)~~ and thereafter, the greater of (a) $5.0 million and (b) the sum of the operating cash burn (as defined in the SWK Loan Facility Agreement) for the two prior consecutive fiscal quarters then ended (the “Liquidity Covenant”).

The SWK Loan Facility Agreement contains events of default, including, most significantly, a failure to timely pay interest or principal, insolvency, or an action by the FDA or such other material adverse event impacting the operations of Aziyo. As of ~~September~~June 30, ~~2022,~~2023, we were in compliance with the financial covenant and all other covenants.

On May 12, 2023, we entered into a first amendment to the SWK Loan Facility Agreement with SWK and the other lenders party thereto. The amendment is described in further detail in Note 6 to the condensed consolidated financial statements included elsewhere in this Quarterly Report.

Supplier Promissory Note

During 2017, we restructured certain of our liabilities with a tissue supplier and entered into an unsecured promissory note bearing interest at 5%. As of June 30, 2022, the balance of this promissory note totaled $1.4 million plus

Table of Contents

accrued interest. In connection with the August 2022 debt refinancing, we used $1.4 million of the proceeds from the SWK Loan Facility to repay the remaining balance on the promissory note, and as of June 30, 2023, we had no balance remaining on the promissory note.

Funding Requirements

We expect to continue to incur significant expenses and operating losses for the foreseeable future as we expand our product development and clinical and research ~~activities and to the extent we grow our sales organization to coincide with product launches.~~activities. In addition, we expect to continue to incur significant costs and expenses associated with operating as a public company.

As of ~~September~~June 30, ~~2022,~~2023, we had ~~$20.0~~$24.9 million of indebtedness outstanding, consisting of ~~$21.0~~$25.8 million outstanding under our SWK Loan Facility (net of ~~$1.0~~$0.9 million of unamortized discount and deferred financing costs). In addition, as further described in Note 7 to ~~the~~these condensed consolidated financial statements included elsewhere in this Quarterly Report, we are party to a royalty agreement with Ligand Pharmaceuticals Incorporated (“Ligand”) pursuant to which we assumed a restructured, long-term obligation to Ligand (the “Revenue Interest Obligation”), that requires us to pay Ligand 5.0% of future sales of the products we acquired from CorMatrix (as well as products substantially similar to those products), subject to annual minimum payments of $2.75 million. Furthermore, a $5.0 million payment will be due to Ligand if cumulative sales of these products exceed $100 million and a second $5.0 million will be due if cumulative sales exceed $300 million during the ten-year term of the agreement which expires on May 31, 2027. ~~We are currently forecasting that the~~The initial $5.0 million milestone payment ~~will become payable~~became due in ~~mid-2023.~~the second quarter of 2023.

If our available cash balances and cash flow from operations ~~if any,~~ are insufficient to satisfy our liquidity requirements, we may seek to raise additional capital through equity offerings, debt financings, or asset sale or ~~licensing~~other transactions. However, such transactions may not be successful and we may not be able to raise additional equity or debt, or sell or license assets on acceptable terms, or at all. We may also consider raising additional capital in the future to expand our business, pursue strategic investments or take advantage of financing opportunities. Our present and future funding requirements will depend on many factors, including, among other things:

●

continued patient, physician and market acceptance of our products;

●

the scope, rate of progress and cost of our current and future pre-clinical and clinical studies;

~~Table of Contents~~

●

the cost of our research and development activities and the cost and timing of commercializing new products or technologies;

●

the cost and timing of expanding our sales and marketing capabilities;

●

the cost of filing and prosecuting patent applications and maintaining, defending and enforcing our patent or other intellectual property rights;

●

the cost of defending, in litigation or otherwise, any claims that we infringe, misappropriate or otherwise violate third-party patents or other intellectual property rights;

●

the costs of defending against or the damages payable in connection with the FiberCel Litigation and any future litigation that we may be subject to (to the extent above the applicable insurance coverage);

●

the cost and timing of additional regulatory approvals;

●

costs associated with any product recall that may occur;

●

the effect of competing technological and market developments;

●

the expenses we incur in manufacturing and selling our products;

Table of Contents

●

the extent to which we acquire or invest in products, technologies and businesses in the future, although we may currently have no commitments or agreements relating to any of these types of transactions;

●

the costs of operating as a public company;

●

unanticipated general, legal and administrative expenses; and

●

the effects on any of the above of the current COVID-19 pandemic or any other pandemic, epidemic or outbreak of infectious disease.

In addition, our operating plans may change as a result of any number of factors, including those set forth above and other factors currently unknown to us, and we may need additional funds sooner than anticipated. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt ~~financing and preferred equity~~ financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, creating liens, redeeming shares of our common stock and/or declaring dividends. If we raise funds through collaborations, licensing agreements or other strategic alliances, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay the development or commercialization of our products, license to third parties the rights to commercialize products or technologies that we would otherwise seek to commercialize and reduce marketing, customer support or other resources devoted to our products or cease operations. See our Annual Report, Part I, Item 1A. “Risk Factors — Risks Related to Our Business — Our future capital needs are uncertain and we may need to raise funds in the future, and such funds may not be available on acceptable terms or at ~~all.~~all.”

Based on our current operating plans, we believe there is uncertainty as to whether our future cash flows along with our existing cash, ~~availability under the SWK Loan Facility,~~ issuances of additional equity and cash generated from expected future sales will be sufficient to meet our anticipated operating needs through twelve months from the financial statement issuance date. Due to these factors, there is substantial doubt about our ability to continue as going concern within one year after the issuance of the financial statements.

~~Table of Contents~~

Critical Accounting Policies and Estimates

The preparation of our unaudited condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect reported amounts and related disclosures. We have discussed the policies and estimates that we believe are critical and require the use of complex judgment in their application in our Annual Report, and, during the ~~nine~~three and six months ended ~~September~~June 30, ~~2022,~~2023, there were no material changes to those previously ~~disclosed, except as noted below.~~disclosed. Refer to Note 2, “Summary of Significant Accounting Policies,” to our condensed consolidated financial statements included elsewhere in this Quarterly Report for information regarding our critical accounting estimates and policies.

~~Contingent Liability for FiberCel Litigation~~

We believe the determination of our Contingent Liability for FiberCel Litigation is a critical accounting policy. We review every lawsuit and claim and are in contact with outside counsel on an ongoing basis. An accrual is established for each lawsuit and claim, when appropriate, based on the nature of each such lawsuit or claim. The provision for FiberCel Litigation claims are based upon many factors, which vary for each case. These factors include (i) the extent of the injuries incurred, (ii) recent experience on settled claims, (iii) settlement offers made to the other parties to the litigation and (iv) any other factors that may have a material effect on the estimated liability. While we believe our estimated liability to be reasonable, the actual loss amounts are highly variable and turn on a case-by-case analysis of the relevant facts. As such, actual settlement amounts may differ from our estimates and such differences may be material.

Recent Accounting Pronouncements

Refer to Note 3, “Recently Issued Accounting Standards,” to our condensed consolidated financial statements included elsewhere in this Quarterly Report for information regarding recently issued accounting pronouncements.

JOBS Act

Section 107 of the JOBS Act permits us, as an “emerging growth company,” to take advantage of an extended transition period for adopting new or revised accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, as a result, for so long as we remain an emerging growth company, unless we subsequently choose to affirmatively and irrevocably opt out of the extended transition period, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the

Table of Contents

effective dates for new or revised accounting standards that are applicable to public companies. Section 107 of the JOBS Act provides that we can elect to opt out of the extended transition period at any time, which election is irrevocable.

We will remain an emerging growth company until the earliest of: (i) the last day of the first fiscal year in which our annual gross revenues are $1.235 billion or more; (ii) the last day of 2025; (iii) the date that we become a “large accelerated filer” as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common equity held by non-affiliates is $700 million or more as of the last business day of our most recently completed second fiscal quarter; or (iv) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the previous three years.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are exposed to market risks in the ordinary course of our business, including risks relating to changes in interest rates, foreign currency and inflation. The following discussion provides additional information regarding these risks.

Interest Rate Risk

Our primary exposure to market risk relates to changes in interest rates. Borrowings under our SWK Loan Facility bear interest at variable rates, subject to an interest rate floor. Interest rate risk is highly sensitive due to many factors, including U.S. monetary and tax policies, U.S. and international economic factors and other factors beyond our control. A hypothetical 10% relative change in interest rates on our variable rate indebtedness outstanding at ~~September~~June 30, ~~2022~~2023 would not have had a material effect on our financial statements. We do not currently engage in hedging transactions to manage our exposure to interest rate risk.

Credit Risk

As of ~~September~~June 30, ~~2022,~~2023, our cash ~~and cash equivalents were~~was maintained with ~~one~~three financial ~~institution~~institutions in the United States. While our deposit accounts are insured up to the legal limit, the balances we maintain may, at times, exceed this insured limit. We believe ~~this~~these financial ~~institution has~~institutions have sufficient assets and liquidity to conduct ~~its~~their operations in the ordinary course of business with little or no credit risk to us.

Our accounts receivable relate to sales to customers. To minimize credit risk, ongoing credit evaluations of all customers’ financial condition are performed. One customer represented 10% or more of our accounts receivable as of September 30, 2022.

~~Table of Contents~~

Foreign Currency Risk

Our business is primarily conducted in U.S. dollars. Any transactions that may be conducted in foreign currencies are not expected to have a material effect on our financial condition, results of operations or cash flows. As we grow our operations, our exposure to foreign currency risk could become more significant.

~~JOBS Act~~

Item 4. Controls and Procedures.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Evaluation of Disclosure Controls and Procedures

The Company’s management has evaluated, with the participation of the Chief Executive Officer and the Chief Financial Officer, the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report. Based on this evaluation, ~~management~~our Chief

Table of Contents

Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of ~~September~~June 30, ~~2022.~~2023.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended ~~September~~June 30, ~~2022~~2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may be involved in claims and proceedings arising in the course of our business. The outcome of any such claims or proceedings, regardless of the merits, is inherently uncertain. For information about legal proceedings in which we are involved, see Note 8 to the condensed consolidated financial statements included elsewhere in this Quarterly Report.

~~Table of Contents~~

Item 1A. Risk Factors.

Our business, financial condition and operating results can be affected by a number of factors, whether currently known or unknown, including but not limited to those described as risk factors, any one or more of which could, directly or indirectly, cause our actual operating results and financial condition to vary materially from past, or anticipated future, operating results and financial condition. For a discussion of these potential risks and uncertainties, see Part I, Item 1A. “Risk Factors” of our Annual Report. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results and the price of our common stock. Except as set forth below, there have been no material changes in our risk factors to those included in our Annual Report.

A substantial portion of our net sales is generated through our commercial partners and independent sales agents, which subjects us to various risks.

We currently rely on the efforts of our commercial partners and independent sales agents to generate a substantial portion of our net sales, and we expect to continue to rely on these third parties to generate a substantial portion of our net sales in the future while we work to grow our direct sales force. For example, we have ~~identified conditions~~commercial agreements with major medical device companies, including Boston Scientific, Biotronik, Sientra and ~~events that raise substantial doubt regarding~~LeMaitre Vascular. As a result, the impairment or termination of these relationships for any reason, or the failure of these parties to diligently sell our products and comply with applicable laws and regulations, has and could in the future materially and adversely affect our ability to ~~continue as~~generate revenue and profits.

One such partner, Surgalign Holdings, Inc. (“Surgalign”) and certain of its direct and indirect subsidiaries commenced voluntary proceedings under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas on June 19, 2023. Total revenues generated by us from Surgalign during the six months ended June 30, 2023 and 2022 were $2.3 million and $2.5 million, respectively. Surgalign is in the process of selling its assets through the chapter 11 process, but our contract with Surgalign is not being assumed by the buyer of the relevant assets. Consequently, future revenues from our Surgalign relationship are highly uncertain.

Because our commercial partners and independent sales agents control the relationships with our end customers, if our relationship with any commercial partner or independent sales agent ends, we will likely also lose our relationship with their customers. Furthermore, our success is partially dependent on the willingness and ability of the sales representatives and other employees of our commercial partners and independent sales agents to diligently sell our products. However, we cannot guarantee that they will be successful in marketing our products. In addition, because our commercial partners and independent sales agents do not sell our products exclusively, they may focus their sales efforts and resources on other products that produce better margins or greater commissions for them or are incorporated into a ~~going concern.~~

As40

Table of ~~September 30, 2022,~~Contents

broader strategic relationship with a partner. Because we ~~had $8.1 million in cash. Based on~~do not control the sales representatives and other employees of our ~~existing cash, availability under the SWK Loan Facility, issuances of additional equity~~commercial partners, we cannot guarantee that our sales processes, regulatory compliance and ~~cash generated from expected future sales, we believe that~~other priorities will be consistently communicated and executed. In addition, we do not have ~~sufficient cash~~staff in many of the areas covered by our commercial partners and independent sales agents, which makes it particularly difficult for us to monitor their performance. While we may take steps to mitigate the risks associated with noncompliance by our commercial partners and independent sales agents, there remains a risk that they will not comply with regulatory requirements or our requirements and policies. Actions by the sales representatives and other employees of our commercial partners and independent sales agents that are beyond our control could adversely impact sales in that territory or result in harm to the reputation of the Company or our products or legal liability, any of which could have a material adverse effect on ~~hand~~our business, financial condition and results of operations. In addition to ~~support current operations~~the risk of losing customers, the operation of local laws and our ~~payment~~agreements with our commercial partners and independent sales agents would make it difficult for us to replace a commercial partner or independent sales agent we believe is underperforming.

In order to increase our sales, we intend to develop relationships and arrangements with additional commercial partners and/or independent sales agents, which we may not be able to do on commercially reasonable terms or at all. If we are unable to establish new commercial partner and independent sales agent relationships and maintain our relationships with our existing commercial partners and independent sales agents, in each case, on commercially reasonable terms, we will be unable to increase sales of our products, which, in turn, could materially and adversely affect our business, financial condition and results of operations.

The loss of one or more significant commercial partners, a material reduction in their purchases of our products, such as what we may experience with Surgalign, or their inability to perform their contractual obligations, ~~under~~including, for example, committed purchase requirements, has affected and could continue to adversely affect our ~~Revenue Interest Obligation~~business, financial condition and results of operations. We are also subject to the risk that any such commercial partner will experience financial difficulties that prevent them from making payments to us on a timely basis or at all.

The processing of human and porcine tissue for ~~at least one year~~our products is technically complex, requiring high levels of quality control and precision, which subjects us to increased production risks.

We manufacture our human and porcine tissue products using technically complex processes requiring specialized facilities, highly specific raw materials, skill and diligence by our personnel and other production constraints. The complexity of these processes, as well as strict company and government standards for the manufacture and storage of our products, subjects us to production risks. In addition to ongoing production risks, process deviations or unanticipated effects of approved process changes may result in non-compliance with regulatory requirements, including stability requirements or specifications. For example, our bone allograft products, such as ViBone and OsteGro V, must be shipped and maintained within a specified temperature range. If environmental conditions deviate from that range, our products’ remaining shelf-lives could be impaired or their safety and efficacy could be adversely affected, making them unsuitable for use. The occurrence of this or any other actual or suspected production or distribution problem can lead to lost inventory, customer returns and, in some cases, recalls, with consequential damage to our reputation and customer relationships and the risk of product liability.

For example, in July 2023, we announced a voluntary recall of a single lot of a certain viable bone matrix product and the market withdrawal of all of our viable bone matrix (“VBM”) products produced after a specified date ~~of issuance~~(“VBM Matter”). Notice of the ~~unaudited~~voluntary recall was issued to centers after the Company learned of post-surgical Mycobacterium tuberculosis (MTB) infections in two patients treated with a VBM product from a single donor lot. Prior to release, samples from this specific lot had tested negative for MTB by an independent laboratory using a nucleic acid test that is designed to specifically detect the MTB organism.

Furthermore, in June 2021, we issued a voluntary recall pertaining to a single donor lot of our FiberCel Fiber Viable Bone Matrix, a bone repair product made from human tissue that is used in various orthopedic and spinal procedures. Notice of the voluntary recall was issued to hospitals that received product from this specific lot following our learning of post-surgical infections in patients treated with FiberCel, including some patients that tested positive for tuberculosis. The lot consisted of 154 units of FiberCel, all derived from a single donor, that were shipped to facilities in 20 states. We have investigated the source of the infections in coordination with our distributor, the FDA and the U.S.

Table of Contents

Centers for Disease Control and Prevention (“CDC”). The FDA inspected our Richmond, California production facility, and this inspection did not result in any Form-483 observations. Additionally, multiple product liability lawsuits have been filed against us in connection with FiberCel. See “We face the risk of product liability claims and may not be able to obtain or maintain adequate product liability insurance” for additional information about these product liability lawsuits.

These product recalls and investigations, as well as others that may occur in the future, and the remediation of any potential or identified problems can cause production delays and result in substantial additional expenses and lost revenue. In addition, we may experience difficulties in scaling up processing and production of our human and porcine tissue products, including problems related to yields, quality control and assurance, tissue availability, adequacy of control policies and procedures and availability of skilled personnel. Furthermore, developing and maintaining our production capabilities has required, and will continue to require, the investment of significant resources, and we cannot guarantee that we will be able to achieve economies of scale. If we are unable to process and produce our human tissue products on a timely basis, at acceptable quality and costs and in sufficient quantities, or if we experience technological problems, delays in production, failure in the storage of our products or other loss of supply, our business would be materially and adversely affected.

We face the risk of product liability claims and may not be able to obtain or maintain adequate product liability insurance.

Our business exposes us to the risk of product liability claims that are inherent in the manufacturing, processing, investigating and marketing of medical devices and human and animal tissue products. For example, since the voluntary recall pertaining to a single donor lot of our FiberCel Fiber Viable Bone Matrix was issued, and since September 2021, we have received notice of 109 separate lawsuits or claims alleging that the plaintiffs contracted tuberculosis and/or suffered substantial symptoms and complications following the implantation of FiberCel during spinal fusion operations. We have settled 27 of these lawsuits for a total of approximately $7.5 million as of June 30, 2023. Of these settled matters, 26 cases were both settled and paid as of June 30, 2023 for a total cash outlay of $7.3 million. For the remaining 82 cases for which settlements have not been reached, we estimated a probable loss related to each case and have recorded a liability at an estimated amount of $14.3 million for a total estimated liability at June 30, 2023 of $14.5 million, which is recorded as Contingent Liability for FiberCel Litigation in the accompanying condensed consolidated balance sheets included in this Quarterly Report. See Part II, Item 1, “Legal Proceedings” and Note 8 to the condensed consolidated financial statements ~~appearing within~~included elsewhere in this Quarterly Report. ~~This~~

We are, and may in the future be, subject to product liability claims and lawsuits, including claims that may result from the VBM Matter noted above, and potential class actions or mass tort claims, alleging that our products have resulted or could result in an unsafe condition ~~raises substantial doubt about~~or injury. Product liability claims may be made by patients and their families, healthcare providers or others selling our ~~ability~~products. Product liability claims may include, among other things, allegations of defects in manufacturing, defects in design, a failure to ~~continue~~warn of dangers inherent in the product, negligence, strict liability or a breach of warranties.

Additionally, we may be subject to product liability claims, proceedings and lawsuits, even if the apparent injury is due to the actions of others or the pre-existing health of the patient. For example, we rely on physicians and other healthcare providers to properly and correctly use our products. If these physicians or other healthcare providers are not properly trained or are negligent in using our products, the capabilities of our products may be diminished or the patient may suffer critical injury. In addition, we may be subject to product liability claims, as well as a ~~going concern for at least one year from~~number of other risks, as a result of physicians and other healthcare providers using our products “off-label.” See the ~~date~~risk factor entitled “The misuse or off-label use of our products may harm our reputation in the marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our ~~unaudited condensed consolidated financial statements for~~business” included in the ~~period ended September 30, 2022 were issued.~~Annual Report.

Defending any current or future claims, proceedings or lawsuits, regardless of merit, could be costly, divert management attention and result in adverse publicity, which could result in the withdrawal of, or reduced acceptance of, our products in the market. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In ~~order~~addition, regardless of merit or eventual outcome, product liability claims may result in:

●

harm to our business reputation;

Table of Contents

●

investigations by regulators;

●

significant legal costs;

●

distraction of management’s attention from our primary business;

●

substantial monetary awards to patients or other claimants;

●

loss of revenue;

●

exhaustion of any available insurance and our capital resources; and

●

decreased demand for our products.

Our product liability insurance is subject to ~~mitigate the current~~deductibles and potential future liquidity issues, we may seek to raise capital through the issuance of common stock, restructure our Revenue Interest Obligation or pursue asset sale or licensing transactions. However, such transactions may not be successfulcoverage limitations, and we may not be able to ~~raise additional equity, refinance~~maintain this insurance. As of June 30, 2023, we have recorded insurance receivables of $8.9 million on our ~~Revenue Interest Obligation,~~balance sheet in respect of our insurance coverage for the FiberCel Litigation product liability losses. However, it is possible that future claims related to the FiberCel Litigation or ~~sell~~other product liability claims could exceed the limits of, or ~~license assets~~be excluded from, coverage under our policies, and claims against us could also increase the cost of maintaining our coverage. If these or other claims are excluded from our coverages, or if we are unable to maintain product liability insurance at an acceptable cost or on acceptable terms with adequate coverage or ~~at all. As~~otherwise protect ourselves against potential product liability claims, or if we underestimate the amount of insurance we need, we could be exposed to significant liabilities, which may harm our business. One or more product liability claims could have a significant adverse effect on our business, financial condition and results of operations.

Defects, failures or quality issues associated with our products could lead to product recalls or safety alerts, adverse regulatory actions, litigation, including product liability claims, and negative publicity, any of which may erode our competitive advantage and market share and have a material adverse effect on our reputation, business, financial condition and results of operations.

Quality is extremely important to us and our customers due to the serious and costly consequences of product failure. Quality and safety issues may occur with respect to any of our products, and our future operating results will depend on our ability to maintain an effective quality control system and effectively train and manage our workforce with respect to our quality system. The development, manufacture and control of our products are subject to extensive and rigorous regulation by numerous government agencies, including the FDA, the competent authorities of the EU member states and similar foreign agencies. Compliance with these regulatory requirements, including but not limited to the FDA’s Quality System Regulation (“QSR”), current Good Manufacturing Practices (“GMPs”) and adverse events/recall reporting requirements in the United States and other applicable regulations worldwide, is subject to continual review and is monitored rigorously through periodic inspections by the FDA and foreign regulatory authorities. If we fail to comply with our reporting obligations, the FDA, the competent authorities of the EU member states or other regulatory authority could take action, including issuance of warning letters and/or untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearance, seizure of our products or delay in the clearance of future products.

The FDA and foreign regulatory authorities may also require post-market testing and surveillance to monitor the performance of approved or certified products. Our facilities and those of our suppliers, commercial partners and independent sales agents are also subject to periodic regulatory inspections. If the FDA or a foreign authority were to conclude that we have failed to comply with any of these requirements, it could institute a wide variety of enforcement actions, ranging from a public warning letter to more severe sanctions, such as product recalls or seizures, withdrawals, monetary penalties, consent decrees, injunctive actions to halt the manufacture or distribution of products, import detentions of products made outside the United States, export restrictions, restrictions on operations or other civil or criminal sanctions. Civil or criminal sanctions could be assessed against our officers, employees, or us. Any adverse

Table of Contents

regulatory action, depending on its magnitude, may restrict us from effectively manufacturing, marketing and selling our products.

If our products do not function as designed, or are designed improperly, we or the third-party manufacturer of such products may withdraw such products from the market, whether by choice or as a result of regulatory requirements. In June 2021, we issued a voluntary recall pertaining to a single donor lot of our FiberCel Fiber Viable Bone Matrix, a bone repair product made from human tissue that is used in various orthopedic and spinal procedures, following our learning of post-surgical infections in patients treated with FiberCel, including some patients that tested positive for tuberculosis. This recall had a negative effect on our business, financial condition and results of operations and resulted in a number of lawsuits filed against us as discussed under the risk factor “ We face significant litigation related to FiberCel” included in our Annual Report. Furthermore, in July 2023, we announced a voluntary recall of a single lot of a certain viable bone matrix product and the market withdrawal of all of our viable bone matrix (“VBM”) products produced after a specified date (“VBM Matter”). Notice of the voluntary recall was issued to centers after we learned of post-surgical Mycobacterium tuberculosis (MTB) infections in two patients treated with a VBM product from a single donor lot. Prior to release, samples from this specific lot had tested negative for MTB by an independent laboratory using a nucleic acid test that is designed to specifically detect the MTB organism. The VBM Matter product recall has had and may continue to have, and any product recall we or a third-party manufacturer may conduct in the future, whether voluntary or required, could also have, a negative impact on our business, financial condition and results of operations, and this effect may be material.

In addition, we cannot predict the results of future legislative activity or future court decisions, any of which could increase regulatory requirements, subject us to government investigations or expose us to unexpected litigation. Any regulatory action or litigation, regardless of the merits, may result in substantial costs, divert management’s attention from other business concerns and place additional restrictions on our sales or the use of our products. In addition, negative publicity, including regarding a quality or safety issue, could damage our reputation, reduce market acceptance of our products, cause us to lose customers and decrease demand for our products. Any actual or perceived quality issues may also result in issuances of physician’s advisories against our products or cause us to conduct voluntary recalls. Any product defects or problems, regulatory action, litigation, negative publicity or recalls could disrupt our business and have a material adverse effect on our business, financial condition and results of operations.

We recently received a Nasdaq notice for failing to comply with listing requirements and there is no assurance we will regain compliance or maintain our Nasdaq listing.

On May 4, 2023, we received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) informing us that, due to our Market Value of Listed Securities (“MVLS”) having been below the minimum of $35 million for 30 consecutive business days, we are not in compliance with the MVLS required for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(b)(2) (the “Market Value Standard”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), we have a period of 180 calendar days from May 4, 2023, or until October 31, 2023, to regain compliance with the Market Value Standard. If we do not regain compliance within the allotted compliance period, including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that our common stock will be subject to delisting.

We intend to monitor our MVLS during the allotted compliance period, and may, if appropriate, evaluate available options to regain compliance by resolving the deficiency under the Market Value Standard, or under Nasdaq’s alternative continued listing requirements. However, there can be no assurance that we will ~~be able~~regain compliance with the Market Value Standard during the 180 day compliance period, secure an extension to ~~continue as~~the 180 calendar day period to regain compliance, or gain or maintain compliance under or with Nasdaq’s other applicable listing requirements.

If we cannot regain compliance with the Market Value Standard or under Nasdaq’s alternative continued listing requirements, and if our common stock is delisted by Nasdaq, it could lead to a ~~going concern.~~number of negative implications, including an adverse effect on the price of our common stock, increased volatility in our common stock, reduced liquidity in our common stock, the loss of federal preemption of state securities laws and greater difficulty in obtaining financing. In addition, delisting of our common stock could deter broker-dealers from making a market in or otherwise seeking or generating interest in our common stock, could result in a loss of current or future coverage by certain sell-side analysts

Table of Contents

and might deter certain institutions and persons from investing in our securities at all. Delisting could also cause a loss of confidence of our collaborators, vendors, suppliers and employees, which could harm our business and future prospects.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

~~On November 10, 2022,~~During the ~~Company entered into an amendment to the SWK Loan Facility Agreement that further extended the~~ ~~minimum liquidity step-up date~~three months ended June 30, 2023, none of ~~November 10, 2022 to November 21, 2022. As amended, the Company is required to maintain a minimum liquidity of $5.0 million until November 21, 2022 and thereafter, the greater of (i) $5.0 million~~our directors or ~~(ii) the sum of the Operating Burn~~officers (as defined in Rule 16a-1 under the ~~SWK Loan Facility Agreement)~~Exchange Act) adopted or terminated any contract, instruction, or written plan for the ~~two prior, consecutive fiscal quarters then ended.~~

purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangement" (as defined in Item 408 of Regulation S-K).

4145

Table of Contents

Item 6. Exhibits.

Exhibit
Number

Description

Form

File No.

Exhibit

Filing Date

Filed/ Furnished Herewith

Description

Form

File No.

Exhibit

Filing Date

Filed/ Furnished Herewith

3.1

Restated Certificate of Incorporation of Aziyo Biologics, Inc.

8-K

001-39577

3.1

10/13/2020

Restated Certificate of Incorporation of Aziyo Biologics, Inc.

8-K

001-39577

3.1

10/13/2020

3.2

Amended and Restated Bylaws of Aziyo Biologics, Inc.

8-K

001-39577

3.2

10/13/2020

Amended and Restated Bylaws of Aziyo Biologics, Inc.

8-K

001-39577

3.2

10/13/2020

4.1

Second Amended and Restated Investor Rights Agreement, dated as of September 14, 2020, among the Registrant and the investors named therein

S-1

333-248788

4.1

09/14/2020

Second Amended and Restated Investor Rights Agreement, dated as of March 14, 2020, among the Registrant and the investors named therein

S-1

333-248788

4.1

09/14/2020

4.2

Specimen stock certificate evidencing the shares of Class A common stock

S-1

333-248788

4.2

09/14/2020

Specimen stock certificate evidencing the shares of Class A common stock

S-1

333-248788

4.2

09/14/2020

4.3

Specimen stock certificate evidencing the shares of Class B common stock

S-1/A

333-248788

4.3

09/30/2020

Specimen stock certificate evidencing the shares of Class B common stock

S-1/A

333-248788

4.3

09/30/2020

4.4

Warrant to Purchase Stock, issued on August 10, 2022, by Aziyo Biologics, Inc.to SWK Funding LLC.

8-K

001-39577

4.1

08/15/2022

Warrant to Purchase Stock, issued on August 10, 2022, by Aziyo Biologics, Inc.to SWK Funding LLC.

8-K

001-39577

4.1

08/15/2022

10.1#

Credit Agreement, dated as of August 10, 2022, between Aziyo Biologics, Inc. and SWK Funding LLC, as Agent and the Lenders from time to time party thereto

8-K

001-39577

10.1

08/15/2022

10.1†

Aziyo Biologics, Inc. Amended and Restated 2020 Incentive Award Plan

Proxy Statement

001-39577

Annex A

04/27/2023

10.2

Amendment Letter, dated as of October 9, 2022 to Credit Agreement, dated as of August 10, 2022, between Aziyo Biologics, Inc. and SWK Funding LLC, as Agent and the Lenders from time to time party thereto

8-K

001-39577

10.1

10/13/2022

Distribution Agreement by and between Aziyo Biologics, Inc. and LeMaitre Vascular, Inc.

10.3

Amendment Letter, dated as of November 10, 2022 to Credit Agreement, dated as of August 10, 2022, between Aziyo Biologics, Inc. and SWK Funding LLC, as Agent and the Lenders from time to time party thereto (as amended by the Amendment Letter dated as of October 9, 2022)

10.4

Form of Restricted Stock Unit Award Agreement (approved August 2022)

31.1

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH

Inline XBRL Taxonomy Extension Schema Document

4246

Table of Contents

~~32.1~~	~~Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.~~	**

~~32.2~~	~~Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.~~	**

~~101.INS~~	~~Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.~~	*

~~101.SCH~~	~~Inline XBRL Taxonomy Extension Schema Document~~	*

101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document	*

101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document	*

101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document	*


101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document	*

104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)	*

* Filed herewith.

** Furnished herewith.

# Annexes, schedules and exhibits have been omitted pursuant to Item 601(a)(5)(b)(2) of Regulation S-K. The Registrant hereby agrees to furnish supplementally a copy of any omitted annex, schedule or exhibit to the SEC upon request.

† Denotes a management contract or compensation plan or arrangement.

4347

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	AZIYO BIOLOGICS, INC.

Date: ~~November~~August 14, ~~2022~~2023	By:	/s/ C. Randal Mills
		C. Randal Mills
		President and Chief Executive Officer
		(principal executive officer)

Date: ~~November~~August 14, ~~2022~~2023	By:	/s/ Matthew Ferguson
		Matthew Ferguson
		Chief Financial Officer
		(principal financial officer and principal accounting officer)

4448